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                “It was only a sunny smile, and little it cost in the giving,  
but like morning light it scattered the night  
and made the day worth living.”  
 
 F. Scott Fitzgerald 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
        To my family
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ABSTRACT 
Crohn´s disease (CD) is often diagnosed in late childhood and early adulthood. Clinical 
findings include abdominal pain, diarrhea, rectal bleeding, perianal lesions, weight loss and 
growth retardation. Extra-intestinal manifestations, strictures and fistulas may complicate the 
disease. The disease course is characterized by a chronic relapsing pattern and disease severity 
varies between individuals. Environmental, genetic and immunological factors influence the 
development of CD. The exact mechanisms are not clear, but there are probably individual 
combinations of aberrations that contribute to the heterogeneity of the disease phenotype. 
NOD2/CARD15 gene polymorphisms are reported in up to 60% of CD patients and are 
associated with ileal disease, more complicated disease behaviour and younger age at onset. 
The diagnosis of CD is based on clinical, endoscopic and radiological findings. Presence of 
epithelioid cell granulomas in intestinal biopsies is one, non-compulsory, criterion of CD, but 
the reason why some patients have granulomas and not others is elusive. The treatment regimen 
of pediatric CD is moving towards an early, more aggressive approach, aiming at preventing 
disease progression and complications, such as growth retardation. However, reliable 
prognostic markers are lacking and it is difficult to predict which patient would benefit most 
from aggressive treatment. 
 
The aim of this thesis is to broaden the knowledge of genetic, histopathological and clinical 
factors that may be related to the disease course of CD in children. 
 
In paper I the prevalence of and influence from the main NOD2/CARD15 polymorphisms in 
Swedish pediatric CD patients is described. NOD2/CARD15 polymorphisms are uncommon; a 
single allele variant is present in only 8.6% of the patients and genotype-phenotype correlations 
are difficult to establish.  
In paper II the correlation between the location of the disease and the age at onset of CD in 
children is investigated. Ileal involvement before the age of nine is rare and the probability of 
ileal disease increases with age until adulthood. Isolated ileitis is seldom found in pediatric CD 
and, consequently, ileal involvement is most often associated with colonic disease. 
In paper III the effects of interleukin (IL)-6 and variants of the IL6 gene on growth is studied 
in an animal colitis model and in pediatric CD patients. In rats with induced colitis, IL-6 causes 
growth suppression. Blocking IL-6 with antibodies results in increased IGF-I levels and 
enhanced growth, but without improvement of the intestinal inflammation or increased food 
intake among the rats. The children studied with the IL6 -174 GG genotype, which previously 
has been associated with higher IL-6 levels, are more growth-retarded at diagnosis compared to 
other genotypes. This indicates a negative influence on growth as a consequence of a higher 
expression of IL-6. 
In paper IV the significance of granuloma findings in biopsies in pediatric CD patients is 
evaluated. A description of clinical characteristics and growth of a pediatric CD cohort 
followed into adulthood is also performed. Granulomas are found in half of the patients at onset 
and are associated with both upper gastrointestinal involvement and a shorter time to initiating 
immune modulating agents (i.e. thiopurines, methotrexate or anti-TNF-α), suggesting an 
association with a more aggressive disease. The follow-up (median 12.3 years) shows that this 
Swedish group of childhood onset CD has more colonic disease and less ileal involvement, and 
that growth impairment is infrequent both at onset and at follow-up.  
 
This thesis adds to the growing knowledge of the etiological and prognostic factors in CD in 
children. Due to the complex pathophysiology of CD and the heterogeneity of the phenotype, 
large-scale, multicenter trials, in which genetic, clinical, serologic and environmental 
information is combined, would be valuable to accurately determine the risks and prognosis for 
each afflicted individual. The ultimate goal is to develop personalized therapy strategies, with 
the aim of improving prognosis and quality of life of patients with this disease. 
 
Keywords: age, colitis, Crohn´s disease, granuloma, growth, ileitis, inflammatory bowel 
disease, interleukin 6, NOD2, pediatrics, prognosis 
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FOREWORD 
I have more than once during my years working as a pediatrician been fascinated by the 
seemingly inexhaustible strength and healing ability among the children, and I have 
also been hit by their positive attitude and spontaneity. On the other hand, I have many 
times been concerned about the situations and conditions their diseases have put them 
in. Unfortunately, I have also been brutally reminded of the vulnerability of the small 
and developing child. 
In the field of pediatric gastroenterology and nutrition I meet children and 
adolescents in all ages from new-born babies up to the age of 18. It is thrilling and 
demanding but also an enormous privilege to follow these young people up to 
adulthood. 
Crohn´s disease, a chronic inflammatory bowel disease, is a life-long illness, but 
not necessarily with life-long symptoms, which can be difficult and disabling for those 
who are affected. It often strikes them in a very sensitive age, physically, socially and 
psychologically. The fact that the pathogenesis is unclear and the course unpredictable, 
as well as the nature of the symptoms (with a frequent need of a bathroom), the 
relapsing course of the disease and the uncertainty of when the next relapse will appear, 
offers difficulties to caregivers, children and their parents. Moreover, it may be time 
consuming and distressing for both children and parents to have frequent doctor visits 
and blood sampling as well as continuous medication, which itself may be associated 
with side effects and long term risks. For me, as a doctor, it is frustrating not being able 
to provide more information about the future, and not knowing who would benefit from 
aggressive treatment right from the start.  
My idea and wish when I started working on this thesis on Crohn´s disease in 
children was to find out more about the disease, the factors that influence the disease 
course and, if possible, also find early markers for predicting the prognosis since this 
could help both me and my colleagues as well as the children. 
 
 
STOCKHOLM, MARCH 2012   
 
Maja Ideström 
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1 INTRODUCTION 
The Nobel Prize in Physiology or Medicine 2011 was recently awarded with one half 
equally to Jules A. Hoffmann and Bruce A. Beutler for their discoveries concerning the 
activation of innate immunity and the other half to Ralph M. Steinman for his discovery 
of the dendritic cell and its role in adaptive immunity.1 They have revealed how the 
innate and adaptive immune responses are activated and thereby provided novel 
insights into disease mechanisms.2,3,4 Thanks to their work, it has been possible to do 
subsequent work on the development of therapy against infections, cancer, and 
inflammatory diseases. 
 
An immune system is necessary for defending ourselves against intruders and 
pathogens, and the response itself, causes an inflammatory process. With an immune 
system that is dysfunctioning we can develop a variety of diseases.5 A total non-
functioning immune system is not associated with life, malfunction gives problems 
with repeated difficult infections, and if the system is not properly configured or 
balanced, there will be reactions towards “self” as in autoimmune diseases or result in 
other chronic inflammatory disorders.  
 
The intestine is the largest immune organ in the body, and as such is the location for 
70– 80% of the body's immune cells.6,7 The epithelium of the bowel is constantly 
exposed to pathogens and foreign material from ingested food and the colon is 
colonized with microorganisms since just after we were born. There is a continuous 
interaction between the epithelium, underlying immune active tissues and the 
microflora in the intestines, balanced by the immune system to maintain the 
homeostasis in health.8 
 
When this homeostasis in the gut is disturbed, as in an infectious inflammation, we may 
develop symptoms. The immune system battles the intruder and when the pathogen is 
defeated, the inflammation is suppressed and homeostasis is restored. If the immune 
system reacts on something normally harmless, fails in eliminating the pathogens or is 
not able to restore the homeostasis, we develop chronic inflammation. There are several 
chronic inflammatory diseases of the gastrointestinal tract and inflammatory bowel 
disease, including Crohn´s disease and Ulcerative colitis, is one. This thesis will mainly 
focus on aspects of Crohn´s disease in children. 
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2 BACKGROUND 
Crohn´s disease is named after Dr Burrill Crohn (1884-1984) who was an American 
gastroenterologist, that made the first description of “regional ileitis” in 1932, based on 
14 cases.9 Even though several case-reports had preceded this paper, it is often regarded 
as the original description of the disease. Initially the condition was believed to be 
limited to the ileum only, but in 1960 Lockhart-Mummery and Morson defined colonic 
Crohn´s disease, which probably had been included within the entity ulcerative colitis 
previously.10 
 
2.1 DEFINITIONS 
Inflammatory bowel disease (IBD) is divided into: 
• Crohn's disease (CD) is a chronic inflammation that can occur throughout the 
gastrointestinal tract. Inflammation is often segmental, discontinuous and 
transmural (involving all intestinal wall layers). Inflammation can be 
accompanied with complications such as perianal abscesses, fistulas and fibrotic 
stenoses. 
• Ulcerative colitis (UC) is a chronic inflammation that occurs in the rectum and 
can spread in oral direction to cover part of, or the entire, colon. The 
inflammation is continuous and usually involves only the mucosa. 
• Indeterminate colitis (IC) or IBD unclassified (IBDU) is a colitis which, 
despite extensive investigations, cannot be distinguished between CD and UC. 
 
2.2 EPIDEMIOLOGY 
Inflammatory bowel disease is often diagnosed in late childhood and early adulthood, 
in the ages between 15 and 30 years, and up to 25% of the patients have their onset 
during childhood.11 The mean age at onset of pediatric CD is between 11 and 13 years 
of age.11 
 
The incidence of pediatric IBD has increased in Sweden in recent decades.12-15 Other 
countries in Europe and North America have also reported a sharp increase, particularly 
in the incidence of pediatric CD, during the same period.16-19 In a study from northern 
Stockholm during the years 1990-2001 there was a marked increase in the number of 
new cases of pediatric CD and a clear predominance of CD compared with UC.13 A 
subsequent study from northern Stockholm 2002-2007 noted that the incidence in 
pediatric IBD has reached a plateau at 12.8 new IBD cases per 100 000 children per 
year and the incidence of CD (9.2/100 000) remains at a high level in international 
comparison (Malmborg P., personal communication).20 It is estimated that 150-200 
children below 16 years of age will develop IBD each year in Sweden. Two out of three 
of these will be diagnosed with CD. 
 
This increase of the incidence has also been reported in adult IBD during the last 10-15 
years,21 but there are large differences in incidence worldwide, varying from as low as 
0.3 cases per 100 000 individuals in China to as high as 20.2 in Canada.21 Even though 
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comparison of the results from different epidemiologic studies is problematic as the 
diagnostic criteria, time periods, design, population size and age groups differ between 
studies, it is obvious that the incidence varies globally. The highest incidence numbers 
are reported from centers in developed, industrial and urbanized countries with high 
socioeconomic status in the population21 and there is an increasing incidence in 
developing areas worldwide, thus changes in lifestyle seem to play an etiologic role.  
 
On the other hand, epidemiological studies have revealed familial and ethnic gathering 
of CD, suggesting a role of genetic factors in the etiology of the disease.22,23 The 
prevalence of IBD is high among Jews, with the highest numbers in Ashkenazi Jews 
and there is different prevalence in various ethnical groups living in the same country.24 
However, in UK there is a significant difference in incidence between the first-
generation immigrants from Asia (low incidence) compared to the second-generation 
(high incidence), indicating that exposure to environmental factors uncovers the 
susceptibility for the disease.25 
 
2.3 ETIOLOGY AND PATHOGENESIS  
Crohn´s disease is a multifactorial immune mediated disease and although the etiology 
and pathogenesis is not fully clear, many putative causes have been studied and 
suggested. Environmental, genetic and immunological factors all contribute and 
interact in the development of CD. The progress in the field of genetics the last decade 
have led to increased knowledge of the pathogenesis of CD by identifying alterations in 
susceptibility genes involved in the inflammatory response. 
  
2.3.1 Genetics 
2.3.1.1 Introduction to genetics and genetic studies 
The mass of genetic information, which is necessary for development and maintenance 
of life, is located in our chromosomes as a chemical code within the DNA molecules. 
Humans have 23 pairs of chromosomes; one copy of each chromosome is inherited 
from the mother and the other from the father. Each chromosome contains several 
genes, which are the functional units of the DNA that encodes a protein. Of all genetic 
material, the genome, only about 1.5% codes for proteins.26 There are between 20,000 
and 25,000 protein-coding genes within that small piece of the genome, the rest 
consists of non-coding DNA.27 Each gene has its specific chromosomal location, called 
a “locus”.  
 
Although any two people share about 99.5% of their DNA sequence, there are a 
number of differences in their genome. The differences can be larger variations such as 
copy number variations (deletions and duplications) and insertions or small variations 
such as a single nucleotide exchange. An allele is one of two or more versions of a gene 
and an individual has two alleles for each gene (one from each parent). If the two 
alleles are the same, the individual is homozygous for that gene, whereas if the two 
alleles differ she is heterozygous. 
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A change in the genetic code can either represent a mutation or a polymorphism. 
Mutations are changes in the DNA sequence that may cause or contribute to a disease. 
An allelic variant that occurs at a frequency greater than 1/100 within a population is 
referred to as a polymorphism. Polymorphisms may contribute to disease susceptibility 
in complex diseases. 
  
The genotype refers to the genetic code and the phenotype is the characteristics that a 
person or a disease has. A specific genetic alteration may result in different phenotypes 
and a specific phenotype may be the result of (several) different genes, referred to as 
genetic heterogeneity. 
 
Far from all of the variants associated with disease are positioned in the protein coding 
regions of the DNA. Instead, they are often located in the large non-coding regions on 
the chromosome between genes, or in the intron sequences that are edited out of the 
DNA sequence when proteins are processed. These sequences may instead play a role 
in the expression of the genes. Epigenetics is the variety of the human genome that does 
not include variations of the nucleotide sequence in the DNA, for example chromatin 
packaging, histone modifications and DNA methylation. These variations are important 
in regulating gene expression, genome replication and other cellular processes.  
 
In genetic linkage studies, chromosomal regions (loci or alleles) inherited together with 
the disease in families are identified. These regions (candidate regions) are likely to 
harbor susceptibility genes. Alleles that are physically close to one another tend to stay 
together during meiosis and are therefore genetically linked. Linkage disequilibrium is 
the association of alleles at two or more loci, inherited together more often than 
expected. For studying complex diseases, large multiplex families with multiple 
affected individuals are preferable but hard to find. Sib-pair analysis in a large number 
of families is an alternative. 
 
In genetic association studies, the frequency of an allele of a genetic variant is found 
more often than expected in individuals with the disease compared to healthy controls. 
This method is better than linkage studies at detecting weaker genetic associations, as 
in complex diseases. Fine mapping is used when the approximate chromosomal 
location of an association is known, to narrow the region until the candidate gene and 
its alterations are found. 
 
Inheritance studies of genetic linkage in families were the primary method around the 
year 2000, prior to the introduction of genome-wide association studies. In a genome-
wide association study, where high-density single nucleotide polymorphism (SNP) 
array technology is used, hundreds or thousands of SNPs and common genetic variants 
can be studied at the same time to find associations with a specific disease. The 
associated SNPs are then considered to mark regions of the genome which influence 
the risk of the disease. Parallel with development of new technologies and the ability to 
analyze a higher number of SNPs the costs have gradually decreased and the number of 
studies using this technique increases rapidly. One of these technologies is whole-
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exome sequencing, which focuses on all exons (the coding regions of the genome) and 
therefore is less extensive than studies of the whole genome but on the other hand also 
much less expensive. 
 
2.3.1.2 Genetics in Crohn´s disease 
Epidemiological studies, as described above, support the importance of genetic 
influence in the etiology of CD and the mode of inheritance suggests that CD not is a 
simple monogenic Mendelian disorder but a genetically complex disease, where 
multiple susceptibility genes interact with environmental factors.  
 
Familial aggregation in CD has been reported since many years and up to 1/5 of CD 
patients have a first-degree relative with IBD.23,28-30 The risk for CD among offsprings 
of patients with CD is 13 times higher than the risk within the general population.31 
There are studies suggesting concordance in disease location and extra-intestinal 
manifestations between relatives,29,30,32,33 and an association between positive family 
history and younger age at diagnosis.22,30 There are conflicting opinions weather 
genetic anticipation, i.e. lower age at diagnosis and a greater extent of disease in the 
offspring, occurs in CD or not.34,35 
 
Studying twin pairs regarding the concordance of a disease is a way to find out more 
about the relative contribution of genetic and environmental factors to the etiology. 
Monozygotic twins are genetically identical and have, to a high extent, been exposed to 
the same environmental factors early in life. Dizygotic twins also have shared the same 
environment but only half of the genes, in average. The first study on twins with IBD, 
published 1988, showed that monozygotic twins with CD had a much higher 
concordance rate than dizygotic twins with CD and monozygotic twins with UC, 
stating that CD has a strong genetic component and that this is more pronounced in CD 
than in UC.36 Repeated twin studies in Europe have found CD concordance rates for 
monozygotic twins between 33% and 50%, and for dizygotic twins between 3% and 
10%.36-39 
 
During the 1990s the evidence for heritability in IBD, and not least in CD, was growing 
strongly, leading to an intense search for linkage regions and susceptibility genes. In 
1996 the first two genome scans using linkage strategy in IBD were published.40,41 In 
2001 four loci with significant linkage to IBD had been reported on chromosome 16q 
(IBD1), 12q (IBD2), 6p (IBD3) and 14q (IBD4) with the strongest linkage to CD in the 
IBD1 region. The same year, two independent groups identified the first CD 
susceptibility gene, the nucleotide-binding oligomerization domain 2 (NOD2), within 
the linkage region on chromosome 16.42,43 Hugot et al succeeded in their identification 
of NOD2 using a positional cloning strategy, and Ogura et al used both a positional and 
functional gene approach based on the location and the structural similarities to NOD1. 
Hugot et al found three different polymorphisms within the gene, independently 
associated to CD; two single nucleotide polymorphisms (SNPs) (Arg 702Trp / R702W 
and Gly908Arg / G908R) and one frameshift mutation (Leu1007fs / 3020insC). The 
NOD2 gene was suggested by the HUGO gene nomenclature committee to be renamed 
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as C-terminal caspase recruitment domain 15 (CARD15) a few years after Hugot´s 
discovery. Today NOD2 and CARD15 are used synonymously, however NOD2 is the 
official name.44  
 
In the last decade several genome-wide association studies have discovered an 
increasing number of susceptibility genes and SNPs associated with CD, more than 10 
such studies have been performed in adult IBD45 and two in pediatric IBD.46,47 The 
most recent meta-analysis, published 2010, based on 6 genome-wide association 
studies, including both adult and early onset disease, sum up to 71 significant 
susceptibility loci for CD.48  
 
Many of the identified CD loci have previously been described in other chronic 
inflammatory disorders that can be seen clustered within families and individuals with 
CD, suggesting shared genetic risk factors.45 One example is anchylosing spondylitis 
which, like CD, is associated with variants of interleukin (IL) 23 receptor, tumor 
necrosis factor (ligand) super family (TNFSF) 8 and TNFSF15 genes.48 More than 20 
of the identified CD associated loci are also associated with ulcerative colitis. 
 
The precise functional alleles or the causative genes have not been defined in most of 
these loci, and many loci contain multiple genes and some contain no genes, but with 
supposed regulatory functions. Altogether, these 71 loci are suggested to explain not 
more than 23% of the total genetic risk or heritability48 and regardless of all 
achievements in genetic research there are still an enormous number of unexplained or 
unidentified genetic factors, the so called “missing heritability”.49 Nevertheless, all 
studies performed this far have provided important clues into genetic susceptibility and 
pathogenesis of CD and the majority of the identified polymorphisms seems to be 
involved in the immune responses related to the development of chronic inflammation.  
 
2.3.1.3 Polymorphisms associated to Crohn´s disease 
The susceptibility genes that have been found associated to CD can be grouped 
according to their suggested role in the immune system, as shown in Table 1.  
(Note that all 71 loci and genes not are presented in the table). A few of the genetic 
aberrations will be described further below.  
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Table 1. Examples of susceptibility genes associated with Crohn´s disease.
Genes involved in microbe 
recognition by innate 
immune system 
Genes involved in 
autophagy 
Genes involved in lymphocyte 
activation, differentiation, survival 
and growth
NOD2/CARD15  ATG16L1  IL23R, IL27 and IL10
RIPK2  IRGM  IL12B (IL12 and IL23 p40 subunit) 
TNFSF15  LRRK2  IL18RAP,  PTPN 2, PTPN 22 
CARD9  MTMR3  TNF,TNFSF15, TNFRSF6B 
TLR4    STAT3, JAK2, TYK2 
    SULT1A1, SULT1A2, ICOSLG 
    NOD2/CARD15, CCR6
    HLA class I and II 
 
Genes involved in various functions 
 
MUC1, MUC19   constituent of mucus (mucin)
SMAD3, ZMIZI   modulation of TGF‐β and immune tolerance 
CCL2, CCL7, CCL20   leukocyte recruitment and migration 
PSMG1   degradation of intracellular components
ORMDL1  endoplasmic reticulum function and stress response 
SLC22A4 and SLC22A5  
(=OCTN1 and OCTN2)  
mucosal permeability  
TNFSF11 (=RANKL)  osteoclast activity, proliferation of naïve T cells  
 
 
2.3.1.3.1 NOD2/CARD15 
Even though many other CD related genetic variants have been identified since the 
discovery of NOD2/CARD15, this is still one of the individually most important genetic 
variants associated to CD. Up to 50% of adult50 and as much as 60% of pediatric CD 
patients51 carry at least one of the three main NOD2/CARD15 coding variants; Arg 
702Trp, Gly702Arg and Leu1007fs. As more studies have been published, it has 
become clear that the prevalence of these variants varies widely; the allele frequency 
vary from zero (not present) in Asian cohorts52,53 to between 7% and 42% in European 
and North American cohorts.42,54-61 In a meta-analysis of case-control studies involving 
Europeans it was stated that carriage of one or more alleles of the NOD2/CARD15 
variants is associated with a two to 17-fold greater risk of having CD, with the highest 
risk for homozygotes or compound heterozygotes.62 The prevalence of the three main 
variants among healthy individuals is rather high with an allele frequency in Caucasian 
controls of in average 8%, with large geographical variance between 3.5% and 11.5%. 
Despite the increased risk for CD in carriers the disease penetrance is limited, 
confirming that NOD2/CARD15 acts in interaction with other risk factors.63,64  
 
There are several studies on the clinical implications of carriage of one or more 
NOD2/CARD15 variants. The genotype-phenotype data are quite consistent on 
association with ileal disease rather than colonic disease,50,51,55,57,61,65-68 younger age at 
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onset,50,57,66,69,70 and more complicated (stricturing and/or fistulizing) disease 
behaviour.50,55,56,66,68,71,72 Association to young age at onset is suggestive of 
NOD2/CARD15 polymorphisms being more frequent in pediatric CD.  
 
The NOD2/CARD15 gene is located on chromosome 16q12 and consists of two amino-
terminal caspase recruitment domains (CARDs), a centrally located nucleotide binding 
domain and multiple leucine rich repeats (LRRs) at its carboxy-terminal end. The main 
three polymorphisms are all located in or near the LRR region. The gene encodes the 
NOD2 protein, which is a cytoplasmic pattern recognition receptor, involved in 
bacterial recognition and expressed by monocytes, dendritic and epithelial cells, such as 
Paneth cells.73,74 The LRR region of the protein recognizes a fragment of 
peptidoglucan, muramyl dipeptide, found on the surfaces of both Gram-negative and 
Gram-positive bacteria. This recognition leads to activation of nuclear factor kappa 
beta, which regulates the expression of several proinflammatory cytokines that are 
central in the pathogenesis of CD, i.e. tumor necrosis factor (TNF), IL-1, IL-6, IL-8 and 
IL-18. A defect in the NOD2/CARD15 gene gives a deficit in nuclear factor kappa beta 
activation in response to bacterial components.73,75  
 
Lately it has been shown that NOD2 is involved also in several other pathways in the 
immune response.76 One is the muramyl dipeptide mediated activation of NOD2 
inducing the epithelial cells to release defensins, which are antimicrobial peptides that 
protect the mucosa against adherent or invasive microorganisms.77 Another pathway is 
the bacteria clearance mechanism autophagy, that is partly mediated by NOD2 by 
involving the autophagy regulator ATG16L1 (autophagy related 16-like 1).78 
Autophagy has been shown to be impaired in dentritic cells from CD patients with the 
NOD2/CARD15 gene variant.79 Alterations in the ATG16L1 gene have also been found 
to be associated to CD80 and a combination of disease-associated alleles of ATG16L1 
and NOD2/CARD15 synergistically increase susceptibility for CD.81 
 
Moreover, NOD2 has been shown to interact with DUOX2, a ROS (reactive oxygen 
species)-generating enzyme in epithelial cells,82 important for bacterial killing. The 
functional implications of this interaction in CD patients carrying NOD2 genetic 
variants are not clear.  
 
It is also suggested that NOD2 is involved in promoting the production of IL-17; 
NOD2 senses muramyl dipeptide and activates dendritic cells, which elevate their IL-
23 and IL-1 production, and in turn this promotes the development of human Th17 cells 
and IL-17 production. In dendritic cells from CD patients carrying a NOD2/CARD15 
variant, the muramyl dipeptide mediated induction of the IL-17 production was 
impaired, and there was no up-regulation of the IL-23 and the IL-1 expression.83 
 
Although the mechanism is unclear, another interesting reported effect of carriage of 
NOD2/CARD15 gene variants (especially the frameshift mutation Leu1007fs) is 
evidence of increased intestinal permeability, not only in the CD patients but also in 
their non-affected relatives who carry a gene variant.84 Finally, the NOD2 protein has 
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recently been shown to activate antiviral innate immune responses involving interferon 
beta production.85  
 
2.3.1.3.2 Genes involved in autophagy 
ATG16L1 
The protein encoded by ATG16L1 gene is part of a large protein complex that is 
necessary for autophagy, the major process by which intracellular components 
(including microorganisms) are targeted to lysosomes for degradation. The gene is 
expressed in a variety of epithelial and immune cells, most highly expressed in T helper 
cells, cytotoxic T cells and B cells. Defects in this gene are associated to susceptibility 
to both UC and CD,48 especially T300A variants are associated to CD48,80 and certain 
genotypes have been found associated to ileal disease and younger age.81 The exact 
functional consequences of ATG16L1 gene alterations are not known, but they may 
have roles in both epithelial and immunological aspects of CD pathogenesis. 
 
IRGM  
Expression of the immunity-related GTPase family M (IRGM) gene regulates cellular 
autophagy of internalized bacteria. CD is associated with SNPs around IRGM, but not 
in the coding-sequence of the gene. A common deletion polymorphism upstream of 
IRGM that causes alteration in IRGM regulation and thereby affects the efficacy of 
autophagy, is likely the causal variant.86 
 
2.3.1.3.3 Genes involved in lymphocyte activity and life 
IL23R  
IL-23 receptor variants were first described in 2006 and are inversely correlated to 
CD.87 The prevalence of the “protective” IL-23 receptor variant in two pediatric studies 
were 5.5% and 6% in controls and 3% and 2% in CD patients88,89 but no convincing 
phenotype correlations have been found.90 The discovery of this gene as a susceptibility 
gene for CD has added support to the many studies describing the central role of the 
Th17 cell in chronic immune mediated disorders like CD. The relationship between IL-
23 and Th17 will be described further in a coming section. 
 
TNFRSF6B  
Two SNPs associated to CD are located within a region containing several genes 
including the tumor necrosis factor receptor super family member 6B gene 
(TNFRSF6B).46 The gene encodes the decoy receptor 3 and a variant is suggested to 
regulate receptor load, lymphocyte signaling, serum cytokine levels and to induce 
resistance to apoptosis in T cells and intestinal epithelial cells.91,92 Expression of 
TNFRSF6B is increased in intestinal biopsies from IBD patients,46 DCR3 levels are 
elevated in serum from CD patients92 and the effects of the SNPs are most pronounced 
in exclusively colonic CD or pancolitis in UC.91  
 
TNF-α 
Tumor necrosis factor (TNF)-α polymorphisms have been found to be associated to 
susceptibility for CD, in Asian and European cohorts.48,93,94 Some polymorphisms 
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increase the circulating TNF-α level, whereas others decrease the TNF-α transcription 
levels. Levine et al found that the two polymorphisms believed to decrease TNF-α 
levels either were associated to pediatric onset CD and isolated colonic disease (i.e. 
TNF-863C/A polymorphism)95 or were associated with higher mean heights thus 
having a protective effect on height retardation (i.e. TNF-238G/A polymorphism).96 No 
association to milder disease was found with these two polymorphisms. 
 
2.3.2 Environmental factors 
It is known since many years that the presence of microflora in the gut is required for 
intestinal inflammation to occur; in a murine model with certain knock-out mice, the 
animals develop colitis in the presence of normal microflora but not in a sterile 
germfree environment.97 In patients with CD, remission can be induced by diversion of 
the fecal stream98,99 and antibiotics can both induce and maintain remission.100,101 A 
number of different microorganisms have been suggested to be involved in CD 
pathogenesis, and several triggers have been identified, especially agents and pathogens 
that break the mucosal barrier. These include nonsteroidal anti-inflammatory drugs 
(NSAIDs), antibiotics, virus and bacteria (e.g. Mycobacterium avium paratuberculosis, 
non-pylori Helicobacter, adherent-invasive Escherichia coli, Campylobacter species, 
among others)102 and there is today no evidence that a single factor is responsible for 
the development of CD.  
 
Many chronic inflammatory disorders started to increase in Europe in the mid-
nineteenth century (e.g. allergies, inflammatory bowel diseases, autoimmunity, type 1 
diabetes and multiple sclerosis) and all show evidence of defective 
immunoregulation.103 The importance of changes in environment, lifestyle, diet and 
hygiene conditions during this period and the influence on developing diseases has 
been described in “the hygiene hypothesis”,104 later also called “the Old Friends 
hypothesis” by some.105 Rooks et al suggest that in the urban environment there is a 
reduction of organisms that earlier followed man during evolution.105 Some of these 
organisms were essential intestinal microbiota, establishing soon after birth that came 
to play crucial roles in the priming and optimal functioning of immunoregulatory 
pathways that are involved in tolerance of luminal antigens. Others, like helminths, had 
to be tolerated and the immune system was therefore down-regulated.105 The 
inflammatory diseases today may partly be explained by the lack of these 
microorganisms and a dysregulated immune response, so that certain genotypes (which 
have not changed as much the last century), in the presence of certain triggers, can 
develop these diseases.105 A subcomponent of this hypothesis is that a delayed exposure 
to viruses in infancy, and perhaps other early events related to infections or antibiotic 
treatment, will exacerbate the immunoregulatory deficit. 
 
The change in the commensal flora not only means a regulatory impairment, but also an 
actual lack of certain species that holds anti-inflammatory properties. In rural areas in 
developing countries, inflammatory bowel disease is still unusual. When comparing 
feces from children from rural Africa and Europe, the European children have less 
short-chain fatty acids (SCFAs),106 which have a protective anti-inflammatory role in 
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the gut107 and also significantly less  microbial richness and biodiversity.106 Decreased 
biodiversity has been observed repeatedly in CD patients.108-110 Faecalibacterium 
prausnitzii, an anti-inflammatory commensal bacterium that also generates SCFA, was 
present in the microbiota of the African children106 but has often been lacking in 
European CD patients.110,111 Another example of the symbiosis with the commensal 
flora is the regulatory effect of polysaccharide A, produced by Bacteroides fragilis. In 
an animal model, polysaccharide A is shown to suppress proinflammatory IL-17 
production via anti-inflammatory IL-10 producing T cells.112 Last, analyses of the 
available data conclude that exposure to helminths is one of the environmental factors 
that is most convincingly associated with a low risk of IBD.113,114 
 
Changes in diet not only alter the flora, but may also increase intestinal permeability 
due to the increased consumption of foods containing saponins, lectins, gliadin and 
capsaicin.115 There is some evidence that a very fatty diet can increase permeability and 
that a heavy input of sugars can cause overgrowth of inappropriate intestinal flora.116 
  
Other suggested environmental factors that can interact with the immune system, apart 
from lack of microbiotic and dietary changes, are vitamin-D deficiency, pollution and 
smoking.117 Smoking is repeatedly found as a risk factor for Crohn´s disease.118 
 
2.3.3 Immune defence 
The two basic components of the immune response are the innate and the adaptive 
response. The innate immunity lacks specificity and memory, and is responsible for the 
early initial immune response; to identify and remove the foreign substance119 as well 
as to recruit and activate lymphocytes. It is represented primarily by monocytes, 
macrophages, dendritic cells and neutrophils. The adaptive immunity is characterized 
by clonal expansion of cells, specificity and memory and is mediated by lymphocytes, 
T and B cells, which express antigen receptors on their surface.120 It enhances the 
response upon reinfection and helps the innate immune system when there is an intense 
pathogen load. Although often described separately, there is a frequent crosstalk 
between the adaptive and innate immune systems through the antigen presenting cells, 
cytokines and chemokines, which orchestrate the responses. In CD there is evidence of 
impairment in all levels of defence; the mucosal barrier, the innate immunity and the 
adaptive immunity.  
 
2.3.3.1 Bowel mucosa barrier 
Under normal conditions the gastrointestinal epithelial cells constitute a relatively 
impermeable physical barrier, connected with tight junctions that impede paracellular 
transport. On the luminal side of the epithelial cells, there is a thick layer of mucus, 
composed by mucin glucoproteins, containing defensins, immunoglobulins and other 
molecules with additional anti-microbial and defensive functions. Mucus and its 
content is secreted by enterocytes, lymphocytes and goblet cells, and in the small bowel 
also by Paneth cells. Defects in the mucus layer and its protective functions has been 
shown in CD patients with polymorphisms in the MUC19 gene,121 or with other 
alterations in expression and modifications of mucins,122 and impaired production of 
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defensins has been found in CD patients with CARD15/NOD2 gene variants.77 In CD 
increased intestinal permeability has not only been found during active disease, but also 
in inactive disease123 and in family members of CD patients124 suggesting that this 
could be a primary initiating factor rather than secondary to the inflammation. There 
are other possible reasons for mucosal damage such as viral and bacterial infections, 
trauma, NSAIDs and hypoxia, but an underlying increased permeability or impaired 
barrier function most likely make the mucosa more susceptible to damage. 
 
2.3.3.2 Gut associated lymphoid tissue (GALT) 
The gastrointestinal tract contains the largest mass of lymphoid tissue in the human 
body, called GALT. GALT is made up of several types of lymphoid tissue that store 
immune cells. Peyer’s patches (PP) are aggregates of lymphoid tissue that are spread at 
intervals just beneath the gut epithelium in the small intestine, especially in the distal 
part of the ileum. They consist of B cell follicles located under specialized areas, or 
‘domes,’ of the epithelium known as follicular-associated epithelium, with T cell zones 
in the areas between the follicles. In the follicular-associated epithelium there are multi-
fenestrated M cells (micro fold cells) whose function is to transport luminal antigen into 
the area of the follicle. Between the epithelial cells there are tight junctions, which 
allow the selective entry of fluids, nutrients, and microorganisms. The number of PPs 
that occurs in the intestines seems to be age related and peaks at ages between 15 and 
25 years.125-127 In the colon, instead of PPs, there are isolated lymphoid follicles128 and 
the number, the diameter and the density of these are increasing in inflammatory 
conditions and are important not only for immune surveillance, but also for the mucosal 
regeneration and repair.129 The isolated lymphoid follicles in the colon do not vary with 
age in the same extent as PPs. GALT is of great importance in the development of oral 
tolerance and immunologic homeostasis, accepting the presence of some 
microorganisms (the commensal flora) but not others (the pathogens). When there are 
defects in the epithelial barrier, GALT is exposed to either an excess of, or harmful, 
luminal antigens, resulting in an immune response and mucosal inflammation. The 
lymphoid tissue of the gut, especially the PPs, is suggested to be the potential site of 
onset of CD.130   
 
2.3.3.3 Homeostasis and tolerance 
The healthy mucosal immune system is unique in its ability to protect against invasion 
by pathogens, yet not respond to the commensal bacterial flora or dietary antigens. 
Dendritic cells are antigen presenting cells in the intestinal mucosa that act as guards 
that send signals to the surrounding cells and assist in the assessment of the commensal 
and pathogenic bacteria. Invasive and non-invasive enteric pathogens, but usually not 
commensal flora, trigger the inflammatory cascade through activation of receptors (as 
described below). The toll like receptor (TLR) signalling is kept under control by 
certain inhibitors, such as the Toll-inhibitory protein (Tollip). Prolonged exposure to 
lipopolysaccharides (LPS), which most commensal organisms contain in their cell wall, 
leads to elevated expression of inhibitors which in turn makes the intestinal epithelial 
cells less responsive to TLR-mediated response to commensal microflora. The antigen 
presenting cells also stimulate the activity of regulatory T cells, which in turn produce 
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IL-10, suppress adaptive immune response and also regulate the activity of the innate 
immune system. The mucosal regulation also includes IL-2 and transforming growth 
factor (TGF) β, and altogether this negative regulation of the responses to the 
commensal flora is crucial for maintaining gut homeostasis and oral tolerance.131,132 
 
2.3.3.4 Innate immunity in Crohn´s disease 
In the intestines the first line defence includes the epithelial barrier as described above.  
The intruding microorganisms typically bear certain pattern of molecular structures, 
called PAMPs (pathogen associated molecular patterns). Some of the PAMPs include 
complex macromolecules such as LPS, peptidoglycans, polypeptides (e.i. flagellin), 
and nucleic acids. Receptors of the PAMPs are the pattern recognition receptors, such 
as TLR and NOD proteins (NOD1 and NOD2) and these are expressed by antigen-
presenting cells (i.e. monocytes, dendritic cells and macrophages) and epithelial cells. 
When PAMPs bind to pattern recognition receptors the cells usually respond by 
expressing and/or secreting a characteristic pattern of cytokines (IL-1β, TNF, IL-6, IL-
8 and IL-12), adhesion molecules, and major histocompatibility complex (MHC) class 
II. A major convergent pathway in this response is through MyD88 (myeloid 
differentiation primary response protein), which via IL-1 receptor-associated kinase 
(IRAK) and TNF receptor-associated factor 6 (TRAF6) activates kinases that degrade 
inhibitory molecules, leading to the nuclear factor kappa beta (NF-κΒ) translocation 
into the nucleus. NF-κB activates genes for the inflammatory response.131 
 
The secretion of proinflammatory molecules leads to the recruitment of a wide variety 
of effector cells, including neutrophils, monocytes, lymphocytes and eosinophils to the 
infected or damaged area. Neutrophils, tissue macrophages and newly recruited 
monocytes, which differentiate into macrophages, kill microorganisms through 
phagocytosis. The granules of the neutrophils and the lysosomes of the macrophages 
contain cationic proteins, defensins, cathepsin, proteolytic enzymes, lysozyme, 
myeloperoxidase, toxic oxygen products and lactoferrin that kill the pathogen. Natural 
killer cells can nonspecifically kill virus infected and tumor cells, and eosinophils have 
granules which contents are effective in killing certain parasites, but take part also in 
the unspecific response. Opsonization by antibodies or complement factors, for 
phagocytosis or lysis of the pathogens, facilitates the killing. All these mechanisms of 
defence also contribute to the tissue damage. 
 
As mentioned before, there is evidence that defects in the innate immune response in 
CD result in both high levels of proinflammatory cytokines and impaired clearance of 
pathogens. Associations to polymorphisms in genes involved in pathogen recognition, 
such as NOD2/CARD15 and TLR4, as well as in genes coding important cytokines, 
such as TNF and IL-10, have been confirmed in large genome-wide association 
studies.48 A number of polymorphisms associated to CD susceptibility are located in or 
near genes involved in autophagy (ATG16L1, IRGM, LRRK2, MTMR3).48 Autophagy is 
an essential, homeostatic process by which cells degrade their own components (e.g. 
unwanted organelles). Originally this pathway was known as cell adaptation to 
starvation, but it is now also known as a process of lysosomal degradation of other 
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intracellular components (including microorganisms), as well as antigen presentation 
via MHC class II molecules, thus playing a role in both innate and adaptive immune 
response.133 The importance of autophagy is emphasized by the large number of 
immune-related signalling molecules that regulate autophagy such as different PAMPs 
and damage-associated molecular patterns (DAMPs) (e.g. adenosine-5'-triphosphate 
(ATP), ROS, misfolded proteins, heat-shock proteins, high-mobility group box 
(HMGB) proteins, pathogen receptors, IFN-γ, TNF-α, inhibitor of NF-κB and NF-
κB).134  
 
The importance of the dendritic cells in CD has also been studied and it is suggested 
that dentritic cells falsely recognize commensal bacteria, induce a proinflammatory 
immune response, activate the adaptive immunity and prolong the survival of activated 
T cells, thereby maintaining the inflammation. The mechanisms are not fully known, 
but exaggerated or dysregulated receptor responses on PAMP recognition as described 
above, with known genetic aberrations, may be part of the explanation. CD patients 
have shown to have increased number of activated mucosal dendritic cells and even in 
remission states those dendritic cells secrete more TNF-α and IL-8, and express more 
TLR4, which may suggest an abnormal LPS response and/or a regulatory 
dysfunction.135  
 
A primary failure in the acute inflammation due to macrophage dysfunction has been 
suggested as the reason for CD by Segal and his group. They showed impaired 
accumulation of neutrophil granulocytes to traumatized bowel mucosa in CD patients 
as well as to a “skin window” model, and reduced local levels of IL-8 and IL-1β.136,137 
The underlying reason for this was a disordered macrophage cytokine secretion due to 
degradation of the cytokines in the cell lysosomes, resulting in a much lower clearance 
of bacteria.138 
 
The aberrant response to microorganisms and/or impaired clearance of pathogens 
which follow various defects in the innate immune response in CD, may lead to 
granuloma formation (that will be described further on) and an overactivated or 
dysregulated secondary, adaptive immune response.  
 
2.3.3.5 Adaptive immunity in Crohn´s disease 
The recognition by the adaptive immune system of antigens from the commensal flora, 
or other microorganisms presented by innate immune system, in combination with the 
stimulation that the innate immune system provides, play an important role in the 
pathogenesis of IBD. Cells from both the innate and adaptive immune systems have the 
ability to kill and remove the invaders and they also enhance each other´s actions,120 
partly through the release of various cytokines.  
The adaptive immune system consists of B and T lymphocytes, which through a highly 
diverse antigen receptor repertoire have the ability to recognize all possible antigens. B 
lymphocytes can differentiate into plasma cells and produce specific antibodies. 
T lymphocytes are divided into T helper (Th) cells, which are marked by the co-
receptor CD4 on the cell surface and cytotoxic T cells, which express CD8. These cells 
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recognize antigenic peptides bound to MHC class II and class I molecules, respectively. 
Depending on the cytokine milieu, the T helper cells will differentiate or mature into 
subsets of helper cells as shown in Figure 1. (Adapted from Brand 139 with permission). 
 
 
Figure 1. The cytokines involved in the development of Th1, Th2, Th17 and Treg cells from 
naïve CD4+ cells (marked in red) and the main effector cytokines of these Th subtypes 
(marked in blue). Cytokines which inhibit the Th17 cells are marked in black. * IL35 is only produced 
by murine Tregs. FOXP3 =forkhead box P3; STAT =signal transducer and activator of transcription; T‐
bet =T box expressed in T cells. 
 
The regulatory T cells (FoxP3+, T regs) are active regulators of immune responses and 
play an important role not only in keeping the gut homeostasis, but also in the 
termination of immune responses, by the ability to suppress activated T cells and by 
regulating the activity of the innate immune system. The mechanisms for their 
regulatory activity can be cytokine-independent but also cytokine-mediated by TGF-β 
and IL-10 from the innate immune system. In CD the homeostasis is obviously not 
maintained, and the activation of the immune response is not terminated as it should, 
therefore the function of the T regs has been suggested as an important part of CD 
pathogenesis.132 
 
Both Th1 and Th2 cells have been shown to cause chronic gut inflammation. CD has a 
predominately Th1 cytokine profile; the proinflammatory IL-12 promotes the 
development of Th1 effector cells, which produce INF−γ, TNF-α and IL-2. 
IL2
TNFα
IL6
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The recent years it has become clear that IL-23, a member of the IL-12 family, has a 
central role in the inflammatory response. IL-23 consists of the p19 and the p40 
subunits, and IL-12 is composed of the p35 and the p40 subunits, thus are they sharing 
the p40 subunit. IL-12 and IL-23 are primarily secreted by activated dendritic cells, 
monocytes and macrophages. As the IL-23 receptor is also expressed by dendritic cells 
and macrophages, it has been proposed that IL-23 secretion can amplify local 
expression of cytokines like IL-1β and TNF-α, which in turn stimulates release of 
additional proinflammatory mediators by stromal, epithelial, and endothelial cells. The 
fact that a genetic variant of the IL-23 receptor gene is known to be associated with 
decreased susceptibility to CD has stressed the importance of this pathway in CD 
pathogenesis. 
 
IL-23 is not only important for the acute and intensive cytokine release, but also for 
promoting the chronic intestinal inflammation87,140 through its ability to support the 
development of a novel subset of Th cells known as Th17 cells.141 The discovery of the 
IL-23 / Th17 immune axis has lead to a paradigm shift; CD has changed from being 
regarded as a Th1 to a Th17 mediated disease.  
 
Th17 cells are characterized by their production of IL-17, IL-22, IL-6, and TNF-α and 
have been associated with chronic inflammation in several diseases (e.g. multiple 
sclerosis, rheumatoid arthritis and psoriasis), as well as CD.142 In murine models the 
Th17 cell lineage differentiation is driven by TGF-β and IL-6, while IL-23 is necessary 
for maintaining the Th17 populations. In humans, TGF-β, IL-1, IL-6, IL-21 and IL-23 
all, separately, have been suggested as responsible for the differentiation of precursors 
into Th17 cells. On the other hand, the Th17 cells may be redirected away from IL-17 
production towards a Th1 phenotype (and INF-γ production) in the absence of IL-23, 
suggesting that Th17 cells may be either unstable or in a non-terminally differentiated 
state.143,144 
 
IL-17, which is the main cytokine released from the Th17 cells, also promotes 
expansion and recruitment of innate immune cells, such as neutrophils. Its receptor, IL-
17RA, is expressed nearly everywhere; on hematopoietic cells as well as many non-
immune cell types such as osteoblasts, fibroblasts, endothelial cells and epithelial cells, 
reflecting the importance of IL-17. In CD, high levels of IL-17 have been found in both 
sera and intestinal biopsies.145-148 
 
In addition to the cytokines mentioned this far there are many more, interacting in a 
complex network, and new discoveries are reported continuously. Many of the 
cytokines that have a large potential in the inflammatory process (e.g. IL-17) are also of 
great importance in the homeostatic state (steady state) of the gut.149  
 
Even though the IL-23/IL-17 immune axis is now accepted as dominating, it does not 
exclude other parallel immune pathways from being involved in the development of 
CD. This means that therapeutic targeting of one axis may not be effective and could in 
fact accelerate another.131 There might be a variation of the expression of Th1 and Th17 
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cytokines along the intestine within the same patient, indicating specific local 
regulation mechanisms.150 Whether it is a Th1 or Th17 response is probably also 
dependent on the duration of the inflammatory process. Kugathasan et al noticed a Th1 
response in the early stage of pediatric CD and a shift to a Th17 response in late 
disease.151 The relative importance of Th1 and Th17 response to inflammation has been 
discussed and there are studies showing that Th1 response is actually quantitatively 
greater and thus more likely to be the driving force of the inflammation.152  
 
To summarize, the constant activity of both the innate and the adaptive immune 
systems, in combination with lack of, or impaired, down regulation leads to continuous 
production of proinflammatory cytokines, recruitment of effector cells and tissue 
damage. It has not yet been possible to point out exactly what has failed in the immune 
response in CD, due to the multilayered and complex nature of the response. There are 
probably individual combinations of aberrations, which contribute to the heterogeneity 
of the disease phenotype.    
 
2.4 CLINICAL PRESENTATION 
The clinical presentation of CD depends on the site, extent and severity of the 
inflammation. See Table 2. The main symptoms are abdominal pain, diarrhea (+/- 
bloody stools), weight loss, and perianal lesions. In children growth retardation and 
delayed puberty might be present.153,154 Concomitant fever, anemia, nausea and fatigue 
can also be seen. Symptoms may be rather discrete even with pronounced intestinal 
inflammation, especially in small bowel disease and in younger children. Extra-
intestinal manifestations may be present at onset, or occur later during the disease 
course and involve joints, skin, eyes, liver, bile ducts, pancreas or blood vessels (i.e. 
vasculitis or thromboembolism). Up to 30% of the patients have fibrostenotic strictures 
or fistulas at onset, and many others develop these complications further on.155-157 The 
disease course is characterized by a chronic relapsing pattern, with exacerbations (flare 
ups) and spontaneous or treatment induced remissions. The duration of the remission 
periods and the intensity of the relapses vary between and within the individuals, and 
the disease course is therefore hard to predict. 
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Table 2. Symptoms and signs at presentation of pediatric IBD.
Symptoms or signs 
at presentation 
Crohn´s disease Ulcerative colitis 
Diarrhea  ++ +++ 
Rectal bleeding   ++ +++ 
Mucus in stool + ++ 
Abdominal pain  +++ + 
Tenesmus  + ++ 
Fever   ++ (+) 
Perianal symptoms   ++ (+) 
Oral ulcers   + ‐ 
Fistulas   ++ ‐ 
Strictures  ++ ‐ 
Palpable mass (in RLQ)   ++ ‐ 
Weight loss  +++ ++ 
Deviation in height  ++ + 
Delayed puberty   ++ + 
+++ = typical, ++ = common, + = may occur, (+) = unusual, ‐  = do not occur                                                                                   
RLQ = right lower quadrant of the abdomen 
 
2.5 DIAGNOSTIC CRITERIA 
There is no internationally accepted "golden standard" that defines exactly what criteria 
that must be fulfilled for the diagnosis of CD or UC. However, as detailed below, a 
patient may be considered to have CD or UC if she has a clinical picture compatible 
with the disease and the work-up, including endoscopy, histology, radiology and 
biochemistry, reveals disease typical findings according to the Porto criteria 2005 
(described more thoroughly below) with the caution that possible differential diagnoses 
have been excluded. 
 
During the 1990s and in the beginning of the last decade, various criteria were used for 
IBD diagnosis. In the Lennard-Jones criteria from 1989,158 CD diagnosis was defined 
as the presence of three of the inclusion features, found in any of the available methods; 
clinical examination, radiology, endoscopy or histology from biopsy or surgical 
specimen. The inclusion features were: a) Mouth to anus, b) Discontinous, c) 
Transmural, d) Fibrosis/strictures, e) Lymphoid aggregates/small aphthoid ulcers, f) 
Mucin retention, and g) Granuloma (which itself was regarded as diagnostic). 
Infections, ischemia, irradiation and lymphoma/carcinoma had to be excluded. 
Basically, those criteria were the same as those in use today but they lacked a definition 
of basic or complete work-up. The Porto criteria were introduced as the result of a 
consensus reached by the inflammatory bowel disease working group of ESPGHAN 
(European Society for Paediatric Gastroenterology, Hepatology and Nutrition) in 2005, 
aiming towards uniformity in the work-up and criteria used for pediatric IBD 
diagnosis.159 Diagnostic findings are summarized in Table 3.  
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Table 3. Endoscopy and histology in IBD (The Porto criteria).
  Crohn´s disease Ulcerative colitis 
Endoscopy 
(and visualization 
 of oral and 
perianal regions) 
Ulcers (aphthous, linear, or stellate)
Cobblestoning 
Skip lesions 
Strictures 
Fistulas 
Abnormalities in oral region # 
Abnormalities in perianal region ¤ 
Segmental distribution 
 
Ulcers
Erythema 
Loss of vascular pattern 
Granularity 
Friability 
Spontaneous bleedings 
Pseudopolyps 
Continuous (proximal extension 
from rectum) 
Histology  Submucosal or transmural 
involvement 
Ulcers, crypt distortion 
Crypt abscesses 
Granulomas  
Focal changes (within biopsy) 
Patchy distribution (between 
biopsies) 
Mucosal involvement 
Crypt distortion 
Crypt abscesses 
Goblet cell depletion  
Continuous distribution 
 
# CD in oral region; lip swelling, gingival hyperplasia and aphthous ulcers                                                                                 
¤ CD in perianal region; deep fissures, fistulas and abscesses                                    
(Adapted from 159 with permission) 
 
2.6 DIAGNOSTIC WORK-UP 
Since the diagnosis of IBD is based on the combination of clinical and endoscopic 
findings (macroscopic and microscopic picture) as well as visualization of the small 
intestine and the exclusion of a number of possible differential diagnoses, it is 
important to strive for a complete work-up in every child. In addition to the laboratory 
tests and the diagnostic procedures, the work-up involves history taking (including 
questions on family history of IBD and parental height and weight), physical 
examination (including inspection of the perianal region and assessment of pubertal 
development) and measurements of height and weight. 
 
2.6.1 Laboratory tests 
Screening blood tests include full blood count, erythrocyte sedimentation rate (SR), C-
reactive protein (CRP), serum levels of urea and creatinine, serum albumin, 
immunoelectrophoresis, liver function tests and screening for celiac disease (tissue 
transglutaminas antibody, tTGA). However, a considerable number of the children with 
mild CD may have normal values for the majority of those markers.160 Fecal 
calprotectin is an unspecific marker for intestinal inflammation, which may guide the 
need for invasive investigation such as endoscopy, and distinguish from functional 
gastrointestinal (GI) disorders.161 Normal levels of fecal calprotectin (<50 
microgram/gram feces) make active disease in the lower GI tract unlikely.162,163 
Infectious causes of enteritis or colitis should be excluded by stool cultures (for 
Salmonella, Shigella, Yersinia, Campylobacter and Clostridium difficile), stool direct 
microscopy (for Giardia lamblia and Entamoeba histolytica) and stool tests for 
Clostridium difficile toxins A and B. However, identification of a pathogen does not 
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necessarily exclude IBD, as the first episode of IBD may present after an enteric 
infection.  
 
2.6.2 Endoscopy 
Endoscopy is considered the golden standard for diagnosing IBD. The last couple of 
decades there have been improvements in the technology and feasibility regarding 
endoscopic examinations in children. The routines have changed from partial 
colonoscopies (rectosigmoidoscopies) in the 1980s, through increasing ileum intubation 
rates during the 1990s (22%-66%),164 towards complete endoscopic examinations, 
including ileocolonoscopy and esophago-gastro-duodenoscopy, in the recent 10 years, 
in agree with the Porto criteria.159,165 All endoscopic procedures in children are 
performed under deep sedation, most often general anesthesia.  
 
Colonoscopy including intubation of the terminal ileum and multiple biopsies for 
histology obtained from all segments of the lower intestinal tract (ileum, cecum, 
ascending colon, transverse colon, descending colon, sigmoid and rectum) is the most 
important investigation to differentiate between CD and UC, and it identifies 
localization and extent of inflammatory disease. Intubation of the terminal ileum with 
terminal ileum biopsies should always be attempted, as isolated ileal inflammation may 
occur in the presence of a normal colon in up to 9% of children with CD.154 In addition, 
visualization of the ileum and ileal biopsies are crucial in the differential diagnosis of 
patients with pancolitis.166 Upper endoscopy with multiple biopsies is also included in a 
full work-up in children, since histology of the upper GI tract may confirm a CD 
diagnosis that would otherwise have been missed in up to one out of four cases.167-169 
 
The macroscopic findings in CD vary and depend on the severity of the disease. The 
features and differences compared to UC are listed in Table 3. Continuous 
inflammation can be seen in CD when there is extent disease, but patchy inflammation 
is more Crohn specific, as well as involvement of multiple sites in the GI tract, other 
than colon.   
 
2.6.3 Radiology 
Imaging of the small bowel is of great importance when doing a work-up for suspected 
IBD and a part of the diagnostic program according to the Porto criteria. The small 
bowel may be abnormal even though the terminal ileum is normal, thus the 
examination might be crucial for a correct diagnosis of CD. The imaging may also give 
information on both extent and possible complications of small bowel involvement 
including stenoses and internal fistulas. The most widely used method for this purpose 
is the small bowel follow through or enema. The advantages are low costs and good 
accessibility, and the disadvantages are the radiation exposure and the discomfort for 
the child. Leukocyte scintigraphy was used for small bowel assessment up in the 1990s, 
but has been found to have insufficient diagnostic sensitivity.170 Magnetic resonance 
imaging is probably a more sensitive and specific method for visualizing the small 
intestines (as well as fistula formations),171-173 and has lately replaced the small bowel 
follow through in many cases.165 In a recent ESPGHAN-endorsed ECCO (European 
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Crohn´s and Colitis Organisation) guideline on pediatric CD, magnetic resonance 
imaging is recommended as primary investigation for small bowel imaging in children 
with IBD.174 Transabdominal ultrasound is noninvasive and may reveal intestinal or 
colonic wall thickening or infiltrate, but does not show subtle inflammatory changes, 
and can be used in follow-up of local bowel changes such as ileocecal involvement. 
Ultrasound can also be performed transanally for the diagnosis of fistulas and 
abscesses. 
 
2.6.4 Histopathology 
Histology is important for correct diagnosis, for assessing the extent and intensity of the 
inflammation. In both CD and UC acute and chronic inflammation with architectural 
changes, loss of glands and branching of crypts are found. In CD submucosal (if biopsy 
includes sufficient submucosal tissue) or transmural involvement (in surgical 
specimen), ulcers, crypt distortion, crypt abscesses, focal changes, patchy distribution 
and granulomas are typical. See Table 3. 
 
Findings in upper endoscopy should be interpreted with caution. A specific lesion, such 
as an aphthoid ulcer or an epitelioid cell granuloma, is typically correlated to CD. Focal 
active gastritis is indeed more frequently seen in CD than in UC but does not reliable 
distinguish between them.175 Nonspecific inflammation in the upper GI tract should not 
be interpreted as CD related, as it may be present in up to 70% of children with 
UC.168,176 
 
2.6.4.1 Granulomas 
A granuloma, which is “the hallmark” in CD, is of noncaseating and nonforeign body 
type and located away from crypts. If it is found near a crypt, it may be confused with 
granulomas that are associated with epithelial destruction and crypt damage and those 
may also be present in UC.177 The CD related epithelioid cell granuloma is a well-
circumscribed, discrete, cluster of epithelioid cells (activated histiocytes/ macrophages 
with homogenous eosinophilic cytoplasm), surrounded by lymphocytes and with, or 
without, well-formed multinucleated giant cells.177,178 Both the innate and the adaptive 
immune systems are involved in the initiation, formation and maintenance of 
granulomas. The development of a granuloma is usually a response to antigenic 
stimulation and is orchestrated through chemokines and cytokines. Evidence for the 
role of microorganisms, and suggested impaired clearance of pathogens, are findings of 
adherent-invasive Escherichia coli DNA within granulomas179 and the ability of the 
same bacteria to induce granuloma formation in a research model.180 An exaggerated 
inflammatory immune response with increased levels of proinflammatory interleukins 
(such as IL-1, IL-6, IL-12, TNF-α and IFN-γ) is necessary for the formation of 
granulomas. Since granulomas are dynamic structures they need continuous stimulation 
from its activated macrophages and/or cytokines from T cells. In line with this the 
macrophages and epitelioid cells within the granuloma have been found to express and 
produce both IL-12 and INF-γ.181 It has also been shown that the granuloma cells 
express class II and co-stimulatory molecules, thus functioning as antigen presenting 
cells182 attracting and interacting with the surrounding T lymphocytes.183  
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There are a number of other granulomatous disorders (e.g. tuberculosis, sarcoidosis, 
chronic granulomatous disease and Langerhans cell histiocytosis) which may give GI 
symptoms accompanied with findings of granulomas in biopsies.184,185 Although there 
are overlapping features, the overall presentation with differences in symptoms and 
signs, normally makes it possible to distinguish between the diseases. 
 
2.7 CLASSIFICATION 
Crohn´s disease is a clinically heterogeneous disorder with a variety of demographic, 
clinical and phenotypic features. Classification of different phenotypes is necessary to 
be able to compare disease characteristics over time and place. It also could improve 
the possibilities to find genotype-phenotype associations and possibly give strength to 
prognostic statements that may influence the choice and timing of future medical and 
surgical treatment. A classification system for CD, regarding age at onset, disease 
location and behaviour (i.e. inflammatory, stricturing and/or penetrating), was 
introduced 1998 at the World Congress of Gastroenterology in Vienna. “The Vienna 
classification” was refined by The Working Party of the 2005 Montreal World 
Congress of Gastroenterology, thereafter called “The Montreal classification”.186,187 In 
2010 a pediatric evidence based modification of the Montreal classification was 
proposed; “The Paris classification”.188 In this classification children are subgrouped 
according to age and growth failure, and upper GI/small bowel involvement is better 
defined. The Vienna, Montreal and Paris classifications are presented in Table 4. Note 
that in the Paris classification it is stressed that the definition of extent and location of 
the inflammation is based on (endoscopic) macroscopically identified mucosal 
ulcerations (or erosions) or bowel wall thickening on radiography188 and therefore not 
based on the combination with microscopic findings, as was done earlier. Regarding 
the definition of IC, it was suggested in the Montreal classification that the IC diagnosis 
could only be used after colectomy and the term IBDU could be used in those who 
could not be classified into CD or UC despite an accurate clinical work-up (and had not 
undergone colectomy).186,187 
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Table 4. Vienna, Montreal and Paris classifications of Crohn's disease.
   Vienna (1998)  Montreal (2006) Paris (2010)
Age at  A1: below 40 y  A1: below 17 y A1a: 0 ‐ <10 y
diagnosis  A2: above 40 y  A2: 17 ‐ 40 y A1b: 10 ‐ <17 y
     A3: above 40 y A2: 17 ‐ 40 y
        A3: >40 y
Location  L1: ileal  L1: terminal ileal ± 
limited cecal disease 
L1: distal 1/3 ileum ± 
 limited cecal disease 
   L2: colonic L2: colonic L2: colonic
   L3: ileocolonic  L3: ileocolonic L3: ileocolonic
   L4: upper L4: isolated upper 
disease* 
L4a: upper disease proximal to 
ligament of Treitz* 
        L4b: upper disease distal to 
ligament of Treitz and proximal 
to distal 1/3 ileum* 
Behaviour  B1: non‐stricturing 
non‐penetrating 
B1: non‐stricturing 
non‐penetrating 
B1: non‐stricturing 
non‐penetrating 
   B2: stricturing  B2: stricturing B2: stricturing
   B3: penetrating  B3: penetrating B3: penetrating
       B2B3: both penetrating and 
stricturing disease 
     p: perianal disease 
modifier 
p: perianal disease modifier 
Growth      G0: no evidence of growth delay 
        G1: growth delay
*  may coexist with L1, L2 and L3, respectively                                
B1 –uncomplicated inflammatory disease without evidence of stricturing or penetrating disease.                                
B2 ‐ the occurrence of constant luminal narrowing demonstrated by radiologic, endoscopic, or surgical examination combined 
with prestenotic dilation and/or obstructive signs or symptoms but without evidence of penetrating disease.                             
B3 ‐ the occurrence of bowel perforation, intraabdominal fistulas, inflammatory masses and/or abscesses at any time in the 
course of the disease (excluding secondary postoperative intra‐abdominal complications and isolated perianal  fistulas).            
B2B3 – the presence of both B2 and B3 phenotypes in the same patient, either at the same moment in time or separately over a 
period of time.  
 
2.8 TREATMENT 
The ultimate goal of treatment is to achieve and maintain clinical, endoscopic and 
histological remission, normal growth and puberty and good quality of life. The 
treatment of children and adolescents with CD needs to be individualized depending on 
a number of factors such as location and severity of the inflammation, the nutritional 
status, medication side effects and age-dependent factors, such as their ability to take 
pills. CD treatment consists of pharmacotherapy, nutritional therapy, surgical treatment, 
and psychosocial support. The responsiveness to treatments varies widely among 
children, as well as adults, with CD.   
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2.8.1 Pharmacological  
The general strategy for treatment is the “step up” model; treatment is started with 
agents that are well known, have few or mild side effects and is suitable for most 
patients. If the first level is insufficient for inducing or maintaining remission, the 
intensity of the treatment is increased to the next step. A combination of two or more 
medications is often used.189,190 The model and treatment options are shown in Figure 
2.  
 
 
  
Figure 2. Treatment of pediatric Crohn´s disease according to the “Step up” model. 
Enteral nutrition for induction and maintenance of remission     
Sulfasalazine and mesalazine for induction and maintenance of remission   
Corticosteroids = Predniso(lo)ne or budesonide for induction of remission   
Antibiotics = Metronidazole or ciprofloxacin for induction of remission and for fistulizing disease
Immunomodulators = Azathioprine, 6‐mercaptopurine or methotrexate for maintenance 
Anti‐TNF‐��(tumor necrosis factor‐alpha antibodies) = Infliximab or adalimumab for induction 
and maintenance of remission in severe, refractory disease and fistulizing disease 
 
 
The treatment regimen of pediatric CD is shifting towards a more aggressive approach 
already at the presentation of the disease. Immunomodulators are introduced early in 
selected patients, aiming at preventing disease progression and complications. The 
indications for early immunomodulating treatment are extensive or severe disease at 
onset.174 
 
2.8.2 Surgical 
Surgical treatment may be considered in children at all stages of treatment for specific 
indications, such as fibrostenosis, localized inflammation or severe pancolitis and in 
children with disease resistant to medical therapies, especially in pre-pubertal or early 
pubertal children with growth failure and localized CD. Surgical interventions may also 
be needed for fistulizing and perianal disease.  
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2.9 SPECIFICITIES IN PEDIATRIC CROHN´S DISEASE 
Compared to CD in adults, pediatric CD has distinct characteristics. These are related 
to gender, disease location, extension and treatment, and thereto severity and 
complications. Growth is naturally one significant difference between adult and 
pediatric CD.  
 
2.9.1 Epidemiology 
The increasing incidence of IBD, especially of CD, follows the same pattern in both 
pediatric and adult populations and this is reported in a previous section. However, 
there are epidemiologic differences related to age. The male to female ratio of CD 
differs in multiple studies when comparing pediatric and adult disease. In adult CD 
there is either an equal ratio, or a slight female dominance, whereas there is a male 
predominance in pediatric CD, especially in prepubertal period. The male to female 
ratio is reported to be approximately 1.5 in children younger than 15 years, 13,155,156 
suggesting an effect of puberty and sex hormones on disease pathogenesis, although the 
mechanisms are not yet clear. 
 
2.9.2 Environment and genetics 
There is some evidence supporting the hypothesis that CD starting earlier in life is more 
likely to be influenced by genetic factors than adult onset disease, because of less time 
for impacts by environmental factors.191-194 Genome-wide association studies on 
pediatric cohorts have revealed pediatric risk loci.46 However, those loci have later been 
found significant also in adult CD and the most recent pediatric genome-wide 
association study, published in 2009,47 pointed towards clear genetic similarities 
between pediatric and adult disease. These results, however, do not exclude the 
possibility that pediatric CD is more influenced by genetic factors than adult CD. They 
may all have the same genetic background but the patients with early onset disease 
might have inherited a larger dose of genetic risk factors, or there might be genetic 
factors lying outside the common CD pathways or rare genetic variants modulating age 
at onset, which are difficult to detect. Further studies involving larger pediatric onset 
CD cohorts may reveal new insights. 
 
2.9.3 Disease characteristics 
2.9.3.1 Histopathology and granuloma  
The frequency of granulomas found at histopathologic assessment of biopsies from 
endoscopy or surgical resections is higher in children than in adults and is correlated 
with younger age.195-197 The reported frequency in children varies from 24 to 
61%.195,196,198-200 The incidence of granulomas has been found to be reduced after the 
second year of illness under the influence of treatment and after the 16th year of life,201 
and similarly granulomas are more frequent in untreated than in treated patients.196 The 
reason why some patients with CD have granulomas at onset (and/or later during 
disease course) and not others is elusive, as well as the clinical significance of the 
granuloma findings. 
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Nevertheless, histopathological assessment is of great importance when diagnosing 
inflammatory bowel diseases and a granuloma finding may be the only finding that 
discriminates between the diagnoses. This is especially relevant in children given that 
pancolitis is commonly seen in both pediatric UC and CD, and not least in the youngest 
age group where diagnostics often is more difficult. 
 
2.9.3.2 Disease location and extension 
Disease location differs, for unclear reasons, in pediatric CD compared to adult CD. 
A majority of the children have greater extension of the disease at onset with 
involvement of both ileum and colon or colon only, whereas adults more often have 
terminal ileum disease without involvement of colon.155 Multiple pediatric studies 
have reported colonic involvement, with or without ileal disease, in 60-90% of 
children.11,154-156,202 The reported frequency of isolated colonic disease in all children 
with CD varies between 7% and 38%.11,154,155,157,253 Among children in the youngest 
age group, with disease onset before the age of 5 or 6, isolated colonic disease seems 
to be more common (30-76%)193,203,204 than in children with onset later during 
childhood (20-26%).193,204 Upper GI involvement is also more frequently reported in 
children than in adults, but this may be due to the fact that, unlike in adults, routine 
upper endoscopy is performed in children at onset.  
 
2.9.3.3 Growth and growth failure 
Growth failure is a unique complication of pediatric inflammatory bowel disease, 
especially in CD. Studies from the 1990s, dealing with growth in children diagnosed 
and treated during the 1980s and 1990s, report impaired growth in various frequencies 
up to 65% of the children.153,205,206 However, comparing studies is difficult due to 
different definitions of growth impairment and different study populations. In many 
children decreased growth is present before diagnosis and some do not achieve their 
expected final height. Severity of disease, location of disease (i.e. small bowel 
involvement) and delay (i.e. time from onset of symptoms to CD diagnosis) have all 
been correlated to growth impairment.154,207,208 Hopefully, better awareness of the 
presence and understanding of the pathogenesis of growth impairment, as well as the 
introduction of more effective treatment alternatives, will lead to enhanced growth in 
this group of patients. Indeed, Griffiths studied how the frequencies of linear growth 
impairment (i.e. <-2 standard deviation score [SDS]) have changed over time and she 
noted that the frequency has decreased from fully 20% during the years 1980-86 and 
1990-96 to 7% during 2001-2006.209 
 
Growth retardation may be the only symptom at diagnosis.154 This emphasizes the 
important fact that IBD should be suspected in all children with growth retardation 
where no cause has been found (irrespective of the presence or absence of 
gastrointestinal symptoms) and it is essential to assess growth parameters at onset as 
well as during follow-up in every child. To obtain as much information as possible 
from this assessment, it should include not only height, weight, and body mass index 
(BMI) (preferably transferred into SDS based on appropriate local reference values), 
but also pre-illness data of height and weight and calculation of the growth velocity. 
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Parental height and weight are needed to calculate the target height of the patient.210 
Pubertal delay is often seen and pubertal development should be assessed at onset and 
regularly thereafter.211 Many factors may contribute to growth failure. These are 
summarized in Table 5 (adapted from Griffiths209 with permission from S. Karger AG, 
Basel). 
 
Table 5. Factors contributing to growth impairment in children with Crohn´s disease.  
Factor  Explanation
Decreased or insufficient food intake  Loss of appetite (cytokine mediated) or fear 
of worsening of symptoms  
Increased stool losses  Mucosal inflammation, protein loss 
 
Increased nutritional needs  Ongoing inflammation, fever 
 
Pro‐inflammatory cytokines  Inhibition of IGF‐I and direct negative effect 
on bone growth  
Corticosteroid treatment Interfering with growth hormone and IGF‐I 
 
 
Normal growth is dependent on the growth hormone (GH)/insulin-like growth factor-I 
(IGF-I) axis, as well as thyroxine, cortisol and the sex steroids for growth maintenance. 
IGF-I is produced under the influence of GH and mediates the GH effects at the growth 
plate of bones. Caloric and protein restriction can cause a reduction in the levels of 
IGF-I-binding protein-3 (IGFBP-3), resulting in decreased availability of IGF-I in the 
circulation. The pubertal growth spurt is primarily induced by estrogen, which increase 
the activity of the GH/IGF-I axis. The sex steroids, especially the androgens, appear to 
stimulate growth by a direct effect on growth plate chondrocytes.209 
 
An association between low IGF-I levels and impaired linear growth in children with 
chronic inflammatory conditions, including IBD, is well recognized. However, GH 
production has been shown to be normal, suggesting a degree of hepatic GH 
insensitivity. Mainly undernutrition and inflammatory cytokines are responsible for this 
resistance, but chronic corticosteroid therapy can contribute.212 It is well accepted that 
the use of glucocorticoids contributes to the slowing of growth, although growth 
impairment has also been observed in patients with other chronic inflammatory 
diseases (e.g. systemic and polyarticular juvenile idiopathic arthritis) who have never 
received corticosteroid treatment.213 In CD there is often a nutritional deficit 
contributing to the decreased growth. However, according to studies on pair-fed rats in 
a colitis model, undernutrition accounted for about 60% of the growth impairment, 
whereas the remaining loss in growth resulted from the inflammatory process itself and 
was correlated to a decrease in IGF-I.214  
 
There is a growing mass of evidence that the inflammatory process with its 
proinflammatory cytokines has a direct growth inhibitory effect. The major upregulated 
proinflammatory cytokines found in tissues in CD are, as mentioned previously, IL-6, 
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IL-1β and TNF-α. In animal models they affect longitudinal bone growth by disrupting 
the GH/IGF-I axis.212 The underlying cause of the IL-6 mediated decrease in IGF-I 
production is suggested to be a primary reduction in IGFBP-3 levels, which in turn are 
caused by reduced production and/or increased proteolysis of this binding protein.215 
IL-6 antibodies increase both plasma concentrations of IGF-I and linear growth, 
whereas antibodies against TNF-α increase linear growth but have no effect on plasma 
concentrations of IGF-I.214 Instead, cytokines can act locally on the growth plate level 
where IL-1β and TNF-α in synergy suppress longitudinal growth and this effect can be 
partially reversed by IGF-I.216 In further studies on metatarsal bones from fetal rats, 
normal growth was achieved by TNF-α inhibitor (etanercept) and IL-1β receptor 
antagonist (anakinra) treatment in a dose-dependent way, and combining the treatment 
with IGF-I further improved growth.217 In a review by Walters and Griffiths it is stated 
that chronic IL-6 exposure, in a process independent of IGF-I, promotes osteoclast 
maturation and activation, influence osteoblasts, is associated with osteoclast and 
osteoblast “uncoupling” and results in thinning of the growth plate, but the underlying 
mechanism is yet not known.218 Additionally, cytokines may alter the secretion of 
gonadotropin-releasing hormone and impair end-organ responsiveness to circulating 
testosterone, which may contribute to delayed progress of puberty.219 
 
When a child with CD fails to grow, treatment for their underlying inflammation is 
likely to be inadequate. The treatment should be intensified, adequate intake of calories 
ensured and long-term corticosteroid therapy should be avoided. Exclusive enteral 
nutrition is an appealing alternative in those cases, nocturnal or cyclic supplemental 
enteral nutrition may also improve growth and resection of localized CD should be 
considered when present. Moreover, anti-TNF-α treatment has, in both observational 
and clinical trials data, demonstrated a clear beneficial effect on linear growth (as long 
as treatment is undertaken prior to, or during, puberty) and should be considered in 
these patients in time.209  
 
2.9.4 Disease course and complications 
2.9.4.1 Treatment 
In pediatric patients, who may face lifelong chronic disease, the choice of treatment 
(nutritional, medical, or surgical) is of particular concern. It does not only depend on 
the location and extent of the disease, but also on other factors related to the age of the 
child, such as suitable drug preparations, growth and pubertal stage, non-compliance 
(especially in adolescents) and drug safety issues, due to lack of evidence or safety 
studies in younger children and unknown long-term effects of treatments. The general 
treatment strategies are described in the previous section and here the special 
considerations related to the treatment of children will be reviewed. 
  
Regarding growth there are no specific treatment modalities that have been shown to be 
superior in improving growth, thus focus should be put on controlling disease activity 
and avoid long term use of corticosteroids. In the national guidelines for pediatric IBD 
in Sweden it is stated that exclusive enteral nutrition (EEN, i.e. liquid formula by 
mouth or via tube) is the treatment of choice for pediatric CD, in particular for young 
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individuals in puberty with impaired growth. EEN in children is as effective as 
corticosteroids for induction of remission irrespective of disease activity or location,220 
although there is evidence that children with colonic disease show a better response to 
EEN if there is also ileal involvement.221 EEN has no side effects in contrast to steroids 
and promotes growth. The growth stimulating effect is not only a result of better 
nutrition since anti-inflammatory and growth-stimulating effects actually precede 
restored nutritional status.222 Additionally, EEN but not corticosteroids causes mucosal 
healing.220 It has been shown that sole enteral nutrition is better than partial (i.e. 50% of 
the daily energy intake).223 
 
According to a recent Cochrane analysis, corticosteroid therapy is more effective than 
EEN for inducing remission of CD in adults224 and in adult CD, EEN is therefore 
mostly used when pharmacological treatment is unsuitable or as a supplement to 
pharmacological treatment. There is evidence suggesting that supplementary enteral 
nutrition may be effective for maintenance of remission in CD.225 
 
Unlike the situation in adult CD, 5-Aminosalicylates (5-ASA) are often used in 
pediatric CD. The advantages are that the agents are well tolerated and have few side 
effects. The rational for using them despite lack of evidence for induction or 
maintenance of remission, is that 5-ASAs probably have most therapeutic efficacy in 
colonic disease (regardless of whether the diagnosis is CD or UC) and pediatric CD 
consists of more colonic disease than adult CD.   
 
Biologic therapy, such as TNF-α blockers have proven to be effective in many children 
with moderate to severe CD. Compared to adults, a shorter interval between infusions 
may be beneficial in pediatric CD.226 There is, however, an overall increased risk of 
lymphoma in patients with IBD who have been exposed to biologic or immune 
modulating therapy and a rare fatal form of lymphoma, hepatosplenic T cell lymphoma, 
is linked only to children and young adults with IBD,227 with a predominance in young 
males. For this reason, combination therapy with immunomodulators (i.e. azathioprine, 
6-mercaptopurine and methotrexate) and TNF-α blockers is normally avoided.228  
 
2.9.4.2 Disease severity 
The severity of the disease can be assessed in various ways. Regarding disease 
behaviour, the majority of patients with both adult and pediatric onset disease has an 
inflammatory, non-stricturing, non-penetrating disease phenotype at onset, and 
develops these complications over time.155-157 Stricturing and penetrating disease 
behaviour is most often associated to small bowel disease.155,229 As disease location 
differ between adult and pediatric onset disease, comparing these two groups according 
to complications is somewhat difficult. To overcome this problem Pigneur et al studied 
differences in severity in a childhood onset CD cohort and an adult onset CD cohort 
matched according to disease location (15 years of follow-up) and found that patients 
with childhood onset disease were more likely to have severe disease; the childhood 
onset CD patients had lower final adult height, more active disease, higher frequencies 
of immune modulating and anti-TNF-α therapy but there was no difference regarding 
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the need for surgery (>50% needed excisional surgery in both groups) or frequency of 
complications (i.e. stricture, perforation or perianal disease).230 Adding the suggestion 
from Farmer et al that location is predictive for disease behaviour and prognosis, in 
sense that ileocolonic, rather than purely ileal, involvement predicts a more severe and 
treatment resistant disease course,231 the conclusion might be that pediatric CD is more 
severe than adult CD.  
 
2.9.4.3 Surgery 
Pediatric studies of CD have reported various frequencies of surgery; 28-60% after >10 
years of follow-up.11,230,232,233 The frequency of surgery has been found to be associated 
to stricturing and penetrating disease behaviour, which in turn is associated to the 
disease location (i.e. small bowel) as mentioned above. Similarly, disease limited to the 
colon is associated with less surgery.234  
 
2.9.4.4 Psychosocial complications 
Chronic disease presenting in childhood and adolescence may be associated with 
marked psychological morbidity which has impact on education, relationships, 
psychosexual development and adherence to therapy. There is limited data available 
with various results, but adolescents with IBD might be more depressed and anxious 
and have worse health related quality of life scores than their healthy peers.174 
Therefore, psychosocial support of children and adolescents with CD is important, 
especially in certain vulnerable subgroups.235 Examples of such could be patients with 
severe disease, children with single parents236 (or other family related psychosocial 
factors) or adolescents with growth impairment and accompanying pubertal delay. 
Body image issues including height and weight are among the concerns most 
frequently cited by adolescents with CD in a quality-of-life measure.237 
 
2.10 PROGNOSTIC FACTORS 
In general there is a lack of relevant prognostic factors. Low age per se seems to be a 
negative prognostic factor. There are correlations between disease characteristics and 
complications as described above, although far from all patients with a specific 
phenotype actually develop the associated complications. Small bowel involvement is a 
risk factor for growth impairment, stricturing disease and surgery. Extensive disease 
and upper GI tract involvement at onset have also been reported to be associated to 
severe disease course and early need for immune modulating treatment.238 Current 
smoking is a well known negative prognostic factor for disease recurrence and 
surgery239 although not relevant among the youngest. Genetic alterations, serological or 
immunological markers,240 specific histopathological features (e.g. granulomas), 
response to treatment and remission within a certain time span are examples of possible 
prognostic markers that need to be elucidated further.  
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3 AIMS 
3.1 GENERAL AIMS 
The overall aim of this thesis was to increase the knowledge of CD in children through 
studying genetic, histopathological and clinical factors that may be related to the 
disease course. By correlating these markers to disease characteristics in different ages 
and stages of the disease we may learn to better predict the needs of the individual 
patient. The ultimate aim is to improve the prognosis and the quality of life in the 
affected individual by providing an early individualised anti-inflammatory treatment. 
 
3.2 SPECIFIC AIMS 
The specific aims were: 
 
• to describe the prevalence of the main NOD2/CARD15 polymorphisms in a 
Swedish pediatric CD population 
• to find out the correlation between genotype (regarding NOD2/CARD15 
polymorphisms) and phenotype (characteristics of the disease) in pediatric CD 
• to investigate if and how age at onset correlates to ileal location of the disease in 
children with CD  
• to evaluate the effect of IL-6 on the IGF-I system and linear growth in an animal 
colitis model 
• to analyze whether growth impairment in pediatric CD is correlated to variants of 
the IL6 gene  
• to evaluate the clinical significance of granuloma findings in intestinal biopsies in 
pediatric CD 
• to describe a Swedish pediatric CD cohort followed into adulthood regarding 
clinical characteristics and growth 
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4 MATERIAL AND METHODS 
4.1 STUDY SUBJECTS 
All participating children in papers I and IV (n=58 and n=45, respectively) were 
attending the pediatric gastroenterology unit at Astrid Lindgren Children´s Hospital, 
Stockholm, Sweden, when recruited in 2001 and all were younger than 17 years when 
diagnosed with CD between 1992 and 2001. In paper I the parents (n=106) and 
siblings (>8 years of age, n=44) of the participants were also included for genotypic 
analyses.  
 
In paper II the patients were younger than 16 years of age at CD diagnosis and 
followed at Robert Debre´ Hospital in Paris, France, between 1999 and 2003 (n=136) 
or attending Astrid Lindgren Children´s Hospital in 2002, diagnosed between 1992 and 
2001 (n=55). 
  
The patients included in paper III attended Astrid Lindgren Children’s Hospital 
(n=43), the Royal London and St Bartholomew’s hospitals in London, the Chelsea and 
Westminster, Northwick Park, Bristol Children’s, Lewisham, and Bury St. Edmond’s 
hospitals in England (n=110) and were younger than 16 years when diagnosed with 
CD. Control samples for DNA analyses in paper III were donated from English 
teenagers (n=204) and from adult Swedish blood donors (n=147). For the animal 
studies in paper III, 25-day-old prepubertal Wistar rats from Charles River 
Laboratories were used (n=37).  
 
A presentation of how many patients in papers I-IV were also included in the other 
papers in this thesis is shown in Table 6.  
 
 
Table 6. The number of patients included in multiple papers of this thesis. (In all, 315 
patients were included). 
  Paper I
(n=58) 
Paper II
(n=191) 
Paper III 
(n=153) 
Paper IV
(n=45) 
Paper I (n=58) ‐ 55 32 45
Paper II (n=191) 55 ‐ 32 43
Paper III (n=153)  32 32 ‐ 28
Paper IV (n=45) 45 43 28 ‐
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4.2 METHODS 
In papers I-IV the diagnosis of CD was established according to international criteria, 
corresponding to Lennard-Jones,158 based on clinical, histological, endoscopic, and 
radiological data. The location was determined by findings of macroscopic lesions 
during endoscopy and/or microscopic lesions on biopsies and/or radiologic images 
compatible with CD lesions. In paper IV the disease was classified according to the 
Montreal classification, with the addition of the Paris classification regarding age at 
diagnosis. In paper III only patients with Northern European, Caucasian origin were 
included, because the IL6 -174 polymorphism was previously reported to vary with 
ethnicity.  
 
Clinical data for papers I-IV was retrospectively retrieved from medical records and 
blood samples for genotypic analysis for papers I and III were collected at the same 
time as routine sampling took place. A specialized gastrointestinal pathologist, blinded 
to the clinical status of the children, reviewed the slides prepared from biopsies taken at 
the diagnosis in the majority of the patients in papers I, II and IV regarding location 
and severity of inflammation, and presence of granulomas and their anatomic location 
in the GI tract.  
 
For papers III and IV data on height and weight of the patients at onset were collected 
from medical records and were defined as a measurement within one month of the 
diagnostic endoscopy. Most parental heights were measured for paper III, and in those 
cases measured values were not available for papers III and IV, reported measured 
parental heights were used. At follow-up for paper IV the participants were asked to 
report their present measured height and the measured heights of their parents. Height 
(papers III and IV), weight and BMI (paper IV) were expressed as standard deviation 
scores (SDS) and height at diagnosis and final height was adjusted to target height 210 in 
paper IV. The patients in paper IV were considered to have reached their final height 
when the difference in height was less than 0.5 cm/year. 
  
Genotyping of NOD2/CARD15 (paper I) 
Genomic DNA was isolated from peripheral blood according to standard procedures. 
The three main CARD15 polymorphisms associated with CD (R702W, G908R and 
1007fs) were searched for using primers and methods developed by Lesage et al, as 
described previously.50 For detection of the R702W polymorphism an allele-specific 
polymerase chain reaction assay was used. The G908R variant was detected by a 
restriction enzyme digestion of polymerase chain reaction-amplified DNA (the 
sequence variation create a novel restriction enzyme site). Finally, the detection of the 
1-basepair insertion variant (1007fs) was based on sizing of a labeled polymerase chain 
reaction product after electrophoresis in an acrylamide gel with fluorescently labeled 
primers and automated sequencers. The analyses were performed in the laboratory of 
Fondation Jean Dausset CEPH / INSERM U434 in Paris (France). 
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Genotyping for IL6 promoter haplotypes (paper III) 
Genotyping was performed at the Research Centre for Gastroenterology, Institute of 
Cell and Molecular Science, University of London in United Kingdom. Genomic DNA 
was extracted from fresh blood samples by using a salting-out process, from frozen 
samples by using the Quantikine kit (Amersham Biosciences Corp., Piscataway, NJ, 
USA), and from dried blood spots by using the Chelex technique. High-throughput 
analysis of the IL6 -174 polymorphism was undertaken by using TaqMan 5´ 
endonuclease assay on a 7900 HT sequence-detection system with SDS software 
(Applied Biosystems, Forster City, CA, USA). Details regarding primers can be found 
in the original paper.  
 
Studies on TNBS colitis and control rats (paper III)  
The rats were housed individually in a room temperature of 22°C, with light and dark 
cycles of 12 hours and with free access to standard laboratory chow (RMI cubed; 
Special Diet Services, Witham, U.K.) and tap water. Trinitrobenzene sulfonic acid 
(TNBS) induced colitis was used as a model for intestinal inflammation since it has 
similarities to human disease regarding T cell activation and cytokine profiles (i.e. 
increased IL-6, TNF-α, IL-1, and IFN-γ) and has been shown to inhibit linear growth, 
with a decrease in IGF-I.241  
 
The animals were divided into three groups matched for sex, weight, and body length: 
healthy free-feeding controls (n=13), a TNBS colitis group treated with IL-6 antibodies 
(n=11) and a TNBS colitis group treated with nonspecific sheep IgG antibodies (n=13). 
Under anesthesia (Hypnorm, Janssen Pharmaceutics, Belgium), TNBS (8 mg per 100 g 
of body weight) was inserted 5 cm proximal to the anus in the TNBS colitis groups, and 
in the healthy control group a plastic catheter was passed into the colon and removed 
after one minute. The TBNS colitis rats received either 10–15 mg/kg IgG polyclonal 
antibodies to IL-6 (National Institute for Biological Standards and Control, Potters Bar, 
U.K.) or nonspecific IgG antibodies subcutaneously at induction of colitis and two days 
later. 
  
Daily measurements of body weight, food and water intake were performed. Body 
length (as the mean of two measurements of the distance from nose to tail base) was 
measured at induction of colitis and 5 days later. The animals were killed after 5 days 
by an overdose under anesthetic, trunk blood was collected and the liver and the colon 
were removed (by a midline laparotomy). The severity of the colonic inflammation was 
assessed macroscopically by using a previously validated scoring system (i.e. 
assessment of number and size of ulcers and presence or absence of diarrhea and 
adhesions)242 as well as by measuring the thickness of the colonic wall. A section of the 
colon was assessed for myeloperoxidase activity. Intestinal edema was determined by 
measuring wet and dry weights of the remaining left colon. Plasma and liver 
concentrations of total IGF-I and plasma levels of IGFBP-3 were measured by using an 
ELISA method (Diagnostic Systems Laboratories, Webster, TX, USA). Hepatic IGF-I 
mRNA was measured using specific primers and RT-PCR, see original paper for 
details. 
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4.3 STATISTICAL ANALYSES 
Descriptive data are presented as mean or median with ranges (minimum to maximum 
in papers I and IV and first to third quartiles in papers II and III) according to the 
distribution of data of each variable. In paper III the Kolmogorov-Smirnov test was 
used for examining data and the results are given as SEM (standard error of the mean) 
or median. Differences between groups were assessed by using the Fisher’s exact test, 
students T-test, Chi-Square and linear regression analyses (papers I-IV). 95% 
confidence intervals were calculated for qualitative variables presented as frequencies 
e.g. polymorphism and allele frequencies in paper I and probability for ileal disease in 
paper II. The Mann–Whitney U test / Wilcoxon rank test were used for comparing the 
median times of occurrence of CD depending on the initial localization and the carriage 
of one or more CARD15/NOD2 polymorphisms in paper II, for determining 
differences in CRP and macroscopic scores of colitis in paper III and for comparing 
medians in paper IV. Kaplan-Meier curves with log-rank test are presented for 
comparing the time to event in different subgroups in papers II and IV. Differences 
were generally considered as statistically significant when the p value was less than 
0.05. 
 
SAS 8.02 (SAS, Cary, N.C., USA) and Splus 6.2 (MathSoft, Seattle, WA., USA) 
software packages for PC were used in paper II. The SPSS (version 20.0, SPSS, Inc., 
Chicago, USA) system software and the KIGS Auxology calculator software (version 
1.1, Pfizer, Inc. Sollentuna, Sweden) were used in paper IV. 
 
4.4 ETHICS 
Ethical approvals were obtained from the Regional Research Ethics Committee at 
Karolinska Institutet, Karolinska University Hospital, Stockholm for papers I, II and 
IV. For paper III the human studies committee relevant to each participating hospital 
(including the Regional Research Ethics Committee at Karolinska Institutet, Karolinska 
University Hospital) approved the study. All animal experiments in paper III were 
carried out in London in accordance with the United Kingdom Animal Scientific 
Procedures Act of 1986. 
 
   43 
5 RESULTS 
5.1 PAPER I  
CARD15 mutations are rare in Swedish pediatric Crohn disease 
 
In this study, 58 children, more boys (62%) than girls, participated. Before diagnosis 
they had symptoms for up to 54 months, median duration was 3.6 months and they 
were diagnosed at a median age of 10.9 years (range 2.8 to 16.9 years). Seven children 
(12%) had a first-degree relative with CD. Altogether 21% had a positive family history 
of IBD. 
 
Nearly all patients (97%) had colonic involvement at onset and/or later during the 
disease course and only 57% of the patients had ileal lesions at any time during follow-
up (median 4.2 years). Fifteen % had perianal disease and granulomas were found in 
the initial biopsies in 50% of the children. 
 
The genotyping regarding polymorphisms in the NOD2/CARD15 gene revealed 
polymorphisms in only five patients (8.6%) and all were heterozygous. The distribution 
of the different polymorphisms, as well as the allele frequencies in the children and 
their relatives, are shown in Table 7.   
 
Table 7. Allele frequencies of NOD2/CARD15 polymorphisms in patients and relatives.
Polymorphism  Patients
n=58 (allele %) 
Relatives 
n=150 (allele %) 
R702W   3    (2.6 %) 5    (1.7%)  
1007fsinsC   2    (1.7 %) 4    (1.3%) 
G908R   0 0 
Sum   5    (4.3 %) 9    (3 %) 
 [95% CI] for allele frequency [1.4‐9.8] [1.4‐5.6] 
CI = confidence interval 
 
In the five CD patients carrying a polymorphism, we looked for the parent transmission 
and found the polymorphism in the healthy mother but not in the father in four cases. In 
the fifth family the mother carried another polymorphism than the child, so the 
polymorphism the child had must have been transferred from the father, although we 
did not have DNA to confirm this. This observation can suggest an excess of 
transmission from the mother. Interestingly, none of the five patients had a positive 
family history of CD and all of the relatives with polymorphisms were healthy.  
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The low prevalence of children having one or more of the three NOD2/CARD15 
polymorphisms in this study (8.6%) made testing for a genotype-phenotype relationship 
very difficult. We did note a weak trend towards an excess of granuloma findings in the 
first biopsies in patients with a polymorphism, compared to those with wild type 
NOD2/CARD15 gene, 80% and 43% respectively (p =0.17). 
 
5.2 PAPER II  
Ileal involvement is age dependent in pediatric Crohn´s disease 
 
This study comprised children with CD recruited in Stockholm (n=55) and Paris 
(n=136). The cohorts differed in some aspects regarding sex ratio, disease location at 
diagnosis and NOD2/CARD15 genotypes as shown in Table 8. 
 
Table 8. Comparison between the pediatric CD cohorts from Paris and Stockholm.  
  Paris Stockholm 
Number of patients  136 55
Sex ratio (M/F)  1.0 1.5
Age at diagnosis (median), months  12.0 11.8
Diagnostic delay (median), months  6.0 3.0
Isolated ileal disease, % of patients  6% 7%
Isolated colonic disease, % of patients  31% 56%
Ileocolonic disease, % of patients  63% 36%
NOD2/CARD15 polymorphism carriage 24/44 (55%) 4/55 (7%) 
 
The patients were divided into groups and because of the small number of patients with 
isolated ileal disease (only 12 patients), ileal and ileocolonic disease were merged into 
one group and isolated colonic disease formed the other group. The diagnostic delay 
did not differ between those two groups of patients, 7.0 [inter quartile range 3.0-16.0] 
months and 5.0 [2.0-8.0] months, respectively. 
 
We analyzed the age at diagnosis according to initial localization of the disease for each 
geographic group and for the pooled cohort and found that those with isolated colonic 
disease were younger than those with ileal disease. For the pooled cohort, median age 
at diagnosis was 11 [8-13] years in the group without ileal involvement and 12 [10-14] 
years in the group with ileal disease. The Kaplan Meier curves in Figure 3 show the 
occurrence of isolated colonic and ileal disease in relation to age and the difference 
between the curves was highly significant (p <0.0001). Colonic location occurred as 
early as the age of one year, whereas the youngest child with an ileal location was five 
years old. In both Paris and Stockholm most of the youngest patients show an 
involvement of the large bowel only while small bowel involvement occurred mainly in 
children older than 9 years. This finding was most apparent in the Swedish cohort as 
shown in Figure 3 B.   
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Figure 3. Occurrence of isolated colonic and ileal disease in relation to age.                      
Kaplan‐Meier curves showing the occurrence of colon only (solid line) and ileal (dashed line) CD in 
relation to age in pediatric patients from Sweden and France (A) and from Sweden only (B). 
A 
 
Additionally, we calculated the cumulative probability (95% confidence interval) of 
initial ileal lesions dependent on the age at diagnosis. This probability increased from 
0.0 (0.0-0.48) at the age of 5 years to 0.61 (0.54-0.68) at the age of 16 years, with a 
striking change between the age of 9 years (0.25 [0.12-0.42]) and 12 years (0.57 [0.48-
0.66]). When adding data on carriage of one or more of the main three NOD2/CARD15 
polymorphisms, we found that such carriage was associated with a slightly higher 
probability for ileal involvement at 16 years (0.75 [0.55-0.89]) compared to the 
probability in wild-type patients (0.46 [0.34-0.58]) and the Kaplan-Meier curves were 
significantly different between patients with or without polymorphisms (p <0.02) 
(shown in the original paper). 
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5.3 PAPER III 
Intestinal inflammation-induced growth retardation acts through IL-6 
in rats and depends on the -174 IL-6 G/C polymorphism in children 
 
Anti IL-6 antibodies, IGF-I and growth in TNBS colitis in rats 
The rectal TNBS-ethanol administration to the rats resulted in colitis, extending from 
the splenic flexure to the anus, with bowel wall thickening, edema, skip-lesions, areas 
of ulceration and higher levels of myeloperoxidase in colonic tissue, parameters which 
were assessed when the animals were sacrificed (5 days after induction of colitis). The 
rats with colitis ate less (p <0.001) and had significantly reduced linear growth (p 
<0.001) compared with healthy controls (Figure 4c). Treatment with IL-6 antibodies 
had no significant effect on the severity of colitis, nor did it alter the food intake (p 
>0.05). However, IL-6 antibodies increased linear growth significantly in rats with 
TNBS colitis (p =0.023), but because of the decreased nutrient intake, growth in the IL-
6 antibody-treated rats with TNBS colitis remained less than the healthy controls 
(Figure 4c).  
 
 
 
 
Figure 4. The effects of colitis and IL‐6 antibodies on hepatic IGF‐I, plasma IGF‐I and growth in TNBS 
colitis rats. IL‐6 antibodies increase IGF‐I concentrations in the liver (a), IGF‐1 plasma levels (b) and 
linear growth (c) in rats with TNBS colitis. Growth in the IL‐6 antibody‐treated rats with TNBS colitis 
remained less than the healthy controls because of the decreased nutrient intake (c). 
* p <0.05 vs. controls
** p <0.001 vs. control IgG 
 
 
 
* p <0.001 vs. controls 
** p =0.05 vs. control IgG 
 
 
 
* p <0.001 vs. controls 
** p =0.023 vs. control IgG 
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To evaluate the effect of IL-6 on the IGF-I system, plasma and liver IGF-I levels as 
well as IGF-I expression were analyzed. Administration of IL-6 antibodies significantly 
increased liver IGF-I mRNA and elevated liver and plasma IGF-I concentrations in rats 
with colitis and thus impaired linear growth in TNBS colitic rats was associated with a 
reduction in hepatic and plasma concentrations of IGF-I (Figure 4a and 4b). To 
determine whether a decrease in the binding protein IGFBP-3 contributed to the low 
circulating concentration of IGF-I, IGFBP-3 was also measured. However, the 
concentrations were similar in the rats with colitis and healthy controls indicating that 
the reduction in IGF-I was not caused by a decrease in IGFBP-3. 
 
-174 IL6 G/C haplotype and growth in children with Crohn´s disease 
Previous studies have shown that IL-6 expression is increased in CD and circulating 
levels parallel disease activity. IL-6 induces CRP, which is used clinically to monitor 
disease activity. As described above in our studies on rats, inflammation-related growth 
retardation and decreased levels of IGF-I can be reversed with IL-6 blocking 
antibodies, suggesting that IL-6 levels might be important for growth impairment 
associated to intestinal inflammation also in humans.  
 
IL-6 expression is primarily regulated by alterations in gene transcription. A functional 
G->C SNP at position -174 of the IL6 promoter has been described243 and a certain 
haplotype has been found associated with greater induction of IL-6. We hypothesized 
that patients with the GG genotype express higher levels of IL-6 and therefore they 
would be more growth impaired than patients with other genotypes. To study this 
hypothesis we examined the IL6 -174 genotype in 153 patients with CD from Sweden 
and England. All were diagnosed in the childhood with a mean age at diagnosis of 11.5 
(SD, 2.7) years and 65% of the patients were male. There was no difference in 
genotype distribution between the patients and the 351 controls (p =0.7), between the 
110 English and 43 Swedish children with CD (p =0.8), or between the 204 English 
and 147 Swedish control samples (p =0.8). 
 
At diagnosis the 153 CD children were significantly growth impaired, with a mean 
height SDS of -0.26 (SEM 0.10, p =0.012). The reduced height was regarded as a result 
of their untreated CD, because their parents’ heights were normal; maternal mean 
height SDS was 0.09 (SD 1.09), and paternal mean height SDS was 0.08 (SD 0.89). 
When analyzing growth impairment in relation to the IL6 -174 genotypes, we found 
that children with the IL6 -174 GG genotype were significantly more growth-retarded 
compared with the combined GC/CC group, as shown in Figure 5. 
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Figure 5. Height at diagnosis related to the IL6 ‐174 genotype in children with CD.                             
Height SDS at diagnosis was significantly more reduced in the IL6 ‐174 GG genotype compared with 
the combined GC/CC group, mean height SDS ‐0.51 vs. ‐0.1 (SEM 0.16 vs. 0.13), * p =0.031. 
 
We also wanted to test whether the IL6 genotype is contributory during active 
inflammation, or during both active and inactive inflammation. CRP, which is an acute-
phase respondent that is induced by circulating IL-6, is recorded routinely and in this 
study there were 73 children who had CRP measured both before and after their initial 
therapeutic course. Before therapy, CRP was significantly higher in children with the 
IL6 -174 GG genotype than in those with the GC/CC genotypes (median, 36 vs. 18 
mg/dL, p =0.028). After 6 weeks of treatment, CRP levels were significantly reduced 
from a median of 21.5 to 9.5 mg/dL for all groups (p <0.001). However, after 
treatment, patients with the IL6 -174 GG genotype no longer had higher CRP levels 
compared with the GC/CC group (p =0.68). This means that the IL6 -174 GG genotype 
is associated to higher CRP levels only during active disease.  
 
5.4 PAPER IV 
Pediatric Crohn´s disease from onset to adulthood: granulomas 
may predict a more aggressive disease but growth is not impaired 
 
Altogether 45 of the 58 participants in study I participated in this follow-up study. All 
patients were diagnosed with CD during childhood; median age at diagnosis was 10.3 
years and the median duration of symptoms before diagnosis (delay) was 3.4 months. 
The children were followed into adulthood with a median follow-up period of 12.3 
years (range 9.3-18 years). All but one had reached final height. 
 
The diagnostic endoscopic procedures in this group of patients comprised of 
ileocolonoscopy in 20 children, colonoscopy in 24 children and one patient had an 
emergency surgical procedure at onset. Upper endoscopic examination at diagnosis was 
performed in 26 children.  
 
We found granulomas in 49% (22/45) of the patients in the histopathological 
examination at onset. There was no association between findings of granuloma at 
diagnosis and the age, gender or diagnostic delay. At diagnosis the granulomas were 
found in biopsies from the colon (22/45) and additional granulomas were found in the 
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upper GI tract in two (8%) out of the 26 patients who were examined with upper 
endoscopy and in the ileum in three (15%) of the 20 patients who underwent 
ileocolonoscopy at diagnosis. We found no significant difference regarding number of 
performed endoscopies from diagnosis to the latest follow-up between the patients with 
granuloma findings at onset and the patients without granulomas (mean number 3.6 and 
3.3, respectively, p =0.5), although children with granulomas at onset had a shorter 
follow-up period compared to those without findings of granulomas, 11.7 and 13.2 
years, respectively (p=0.02). As concluded in paper I, colon was the dominating site of 
the disease and the same distribution of disease involvement was found when we 
extracted data on children who had undergone a full ileocolonoscopy at diagnosis, as 
shown in Table 9. 
 
Table 9. Location of the disease at onset and at follow‐up (median 12.3 years) in patients 
with childhood onset CD in Stockholm. 
Location (Montreal 
classification) 
At onset
(n=45) (%) 
At onset, ileo‐
colonoscopy* (n=20) (%) 
At follow‐up
(n=45) (%) 
L1: terminal ileum (+/‐ 
limited cecal disease) 
2 (4.4) 1 (5) 2 (4.4)
L2: colonic  23 (51.1) 10 (50) 19 (42.2)
L3: ileocolonic 20 (44.4) 9 (45) 24 (53.3)
* Data on children who had a full ileocolonoscopy at diagnosis  
 
Upper GI disease (L4) was found in 24.4% of the children at diagnosis and 44.4% at 
follow-up. In total, eleven patients (24%) had increased the extension of their disease at 
follow-up, but only four patients (9%) had a shift in disease extent from only colonic 
(L2) to ileocolonic (L3) during the course of the disease and the rest had additional 
disease extension to the upper GI tract during follow-up. 
 
Findings of granulomas correlated to upper GI involvement in that nine of eleven 
patients (82%) with inflammation of the upper GI tract at onset had granulomas at onset 
(p =0.017). During follow-up, granulomas were found in 17 of 20 patients (85%) with 
upper GI involvement (p =0.006). No significant correlations were found to either 
colonic or ileal disease, nor to developing more extensive disease. 
 
The majority (80%) of the patients (n=36) had non-stricturing, non-penetrating disease 
and there was no correlation between disease behaviour (B1/B2/B3) and findings of 
granulomas at diagnosis (p =0.45). We found a trend towards more granulomas in 
colonic biopsies at onset in children who presented with or developed perianal disease 
(8/11; 73%) as compared to the patients without perianal disease (14/34; 41%), but the 
difference did not reach statistical significance (p =0.07). 
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During follow-up, ten of the 45 (22%) patients underwent a total of 14 surgical 
interventions (six ileocecal resections, three colectomies, three colon resections, and 
two small bowel resections) and the median duration of disease before the first surgical 
intervention was 6.9 years (range 0-12.3). We found no significant differences between 
the group of patients with granulomas at diagnosis and those without regarding 
incidence of surgery or total number of surgical interventions, nor regarding time 
interval from diagnosis to the first surgery, although the granuloma positive group 
seemed to have longer interval compared to the granuloma negative group (median 2.4 
years and 7.8 years, respectively, p =0.29). 
 
Data on immune modulating treatment was used as a proxy for severe disease in this 
study and we therefore also examined whether such therapy was correlated to findings 
of granulomas. Altogether 34 of the total of 45 patients (76%) were treated with 
immune modulating agents, 94% of these were younger than 18 years at start of therapy 
and 20/34 (59%) started immune modulating treatment within one year after diagnosis. 
Interestingly, children treated with immune modulating therapy in the granuloma 
positive group (16/22) had a significantly shorter time from diagnosis to initiating 
immune modulating treatment (median 4.5 months, range 0-75), as compared to the 
children treated with immune modulating therapy in the granuloma negative group 
(18/23) (median 33 months, range 2-105; p =0.01). This finding is shown in the 
Kaplan-Meier curve in Figure 6A. The same trend, although not statistically 
significant, was found regarding treatment with TNF-α blocking drugs (i.e. infliximab 
or adalimumab). See Figure 6B. 
 
Altogether 15/45 patients (33%) were treated with TNF-α blocking drugs, 41 % of the 
granuloma positive patients and 26% of the granuloma negative patients (p =0.29), and 
the disease duration prior to starting TNF-α blocking treatment was 45 months 
(median) in patients having granulomas at onset and 78 months (median) in those 
without granulomas (p =0.09). Additionally, we found that the patients with immune 
modulating or biological treatment had a longer time until the first surgical intervention 
as compared to those without such treatment (p <0.05).   
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Figure 6. Duration of disease at initiation of immune modulating and TNF‐α�blocking treatment. 
Kaplan‐Meier (one minus cumulative survival) curves on the duration of disease at initiation of A) immune 
modulating treatment in patients with such treatment, with and without granuloma findings at onset (p =0.01), 
cumulative frequency 73% and 78% respectively (NS) and B) TNF‐α blockers in all patients with and without 
granuloma findings at onset (p =0.09), cumulative frequency 41% and 26% respectively (p =0.29). 
 
 
 52 
We also set out to use growth impairment as a proxy for severe disease. Weight, BMI, 
height and height adjusted for target height at onset (n=42) as well as final height and 
final height adjusted for target height (n=44) were analyzed and related to Swedish 
national standards. Parental heights were normal, i.e. they did not significantly differ 
from 0 SDS (-0.11 SDS, p =0.33). To our surprise we did not find any significant 
growth impairment in this cohort of pediatric CD neither at onset, nor at follow-up. 
Only one child had a weight less than -2SDS at diagnosis and none had height, height 
adjusted for target height or BMI less than -2 SDS at diagnosis. Among the 44 patients 
that had reached final adult height only one had a final height below -2 SDS, but after 
adjusting final height for target height none was growth retarded. 
 
To rule out the impact of puberty on the results we grouped the children according to 
age and age below 10 was considered as before puberty. In the pre-pubertal group 
(n=18) the median height, weight and BMI at diagnosis were not negatively affected. In 
the group of older children the median height, weight and BMI at diagnosis were below 
0 SDS (-0.19 SDS, -0.42 SDS and -0.46 SDS, respectively), but when adjusting height 
for target height it was not affected (+0.14 SDS).  
 
We also analyzed the possible correlation between growth parameters and the findings 
of granulomas in histopathology of biopsies from the diagnostic endoscopic 
examination. There was no correlation between granulomas at diagnosis and growth 
impairment. Instead the median height SDS (adjusted for target height) at diagnosis in 
the granuloma positive children appeared to be higher than in the granuloma negative 
children (p =0.002). 
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6 DISCUSSION 
We have learnt that genetic, environmental and immunologic factors are of importance 
for the development of CD. Such factors also influence the disease course, the ability to 
respond to different treatment regimens, the complication frequency and the prognosis. 
This thesis has contributed to the growing knowledge of the etiological and prognostic 
factors in CD in children.  
 
6.1 GENETICS AND EPIDEMIOLOGY 
Paper I was the first description of NOD2/CARD15 polymorphisms in a cohort of 
Swedish pediatric patients with Crohn´s disease. Prior to our study other groups had 
reported earlier onset of disease in the presence of polymorphisms,50,57,66 which was 
suggestive of NOD2/CARD15 polymorphisms being more frequent in pediatric forms 
of CD. At the same time, studies on children from the United States and Germany 
showed similar results as the adult studies with carriage prevalence of 29% and 60%, 
respectively.51,244 Thus, it was unexpected to observe such a low percentage of 
polymorphisms as 8.6% in our cohort, strikingly lower than the previous reports from 
other European or North American countries.  
 
Consistent with our findings were reports from other Scandinavian countries, such as 
Finland where 15.5% of the CD patients carried at least one polymorphism55 and 
Norway where the frequency was only 7%.71 Since then, multiple studies have 
confirmed the variation in prevalence of NOD2/CARD15 polymorphisms in CD in the 
general population in different ethnic groups and in different geographic areas.24,63,64,245 
There is no support for the hypothesis that NOD2/CARD15 genetic variants are more 
frequent in children with CD as compared to adults.64 Subsequent studies from Sweden 
have confirmed our finding of a low prevalence of NOD2/CARD15 polymorphisms; 
Halfvarson et al reported NOD2/CARD15 polymorphisms in 13% of Swedish twins 
with CD60 and Törqvist et al reported a prevalence of 15.2% in a Swedish adult CD 
cohort.61 The prevalence in Swedish healthy controls was 5.2% and 4.2% in respective 
study and no combined heterozygotes or homozygotes were found among the 
controls.60,61 Recently, NOD2/CARD15 polymorphisms were reported in 14.2% of CD 
patients in Denmark64 and in 23% of pediatric CD patients in Norway.200  
 
The prevalence of each of the 3 different polymorphisms also varies geographically, as 
well as the prevalence within the healthy population. In a pooled European cohort, 82% 
of the general population carried the wild-type alleles of NOD2/CARD15 and 
homozygosity for polymorphisms is unusual.63 Even though the penetrance of the 
disease is relatively low, there are odds ratios for having CD in heterozygote carriers of 
any polymorphism is between 1.2 and 4.1, and for compound heterozygote or 
homozygote carriers between 3.3 and 17.1, compared to non carriers.62,64 
 
The results regarding the prevalence of NOD2/CARD15 polymorphisms suggest a 
south-north gradient of the distribution. The large geographic heterogeneity is likely 
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related to population history, genetic drift, admixture, and migrations. General 
observations of such gradients for genetic polymorphisms through Europe are 
compatible with a spread of Neolithic farmers from the Levant 10,000 yr ago.246  
 
Contrary to what one might expect, there is an inverse geographic relationship between 
the prevalence of NOD2/CARD15 polymorphism and the CD incidence. Hugot et al 
compared the prevalence of NOD2/CARD15 polymorphisms and the incidence of CD 
in the populations studied, and found a low frequency of NOD2/CARD15 
polymorphisms in Finland where the CD incidence was relatively high while the 
opposite was found in Italy,63 suggesting that NOD2/CARD15 polymorphism frequency 
in the general population does not directly predict a high CD incidence. Similarly, Riis 
et al found significantly lower prevalence of polymorphisms in Denmark and Norway, 
in combination with a high CD incidence, compared to other southern countries in a 
non selected European cohort.245 
 
Regarding the incidence of CD, a north-south gradient has been described in Europe, 
with higher incidences in the northern countries and lower incidences in the southern 
countries (year 1991-1993).247 The same north-south gradient has been reported within 
countries, such as Scotland248 and France.249 A recent study from the US also reported 
that the incidence of CD increased significantly with increasing latitude.250 The reason 
for these observations may of course be different genetic contributions from ancestral 
genes from founder populations settled in these areas, but another suggested reason is a 
relative vitamin-D deficiency in northern (and less sunny) countries or latitudes, which 
could affect the immune system negatively.117,249,251 The increasing incidence of CD in 
some areas252 and a stabilized incidence in others (e.g. Sweden20 and Denmark253) may 
result in a diminished gradient. 
 
The low prevalence of NOD2/CARD15 variants in Sweden opens for speculations on 
other genetic variants important for CD susceptibility in this geographic region. 
Torkvist et al made an analysis of the CD risk loci reported in a previous genome-wide 
association study meta-analysis121 in Swedish IBD patients and the results were only 
partially concordant with previous results. Associations to CD were found for SNPs in 
or near IL23R, IRGM, ZNF365, LRRK2 and C13orf31, best nominal significance were 
found for TNFSF18, IL18RAP, JAK2, CUL2 and NKX2-3 whereas other loci repeatedly 
found in other populations were of small or no relevance (i.e. ATG16L1, NOD2, 
TNFSF15, C5orf56 and PTPN2).254 In an earlier study by Torkvist et al, the IBD5 locus 
was associated with CD in the Swedish population with the strongest association with a 
SNP marker near SLC22A4 and SLC22A5 and a trend towards a more severe disease 
phenotype was observed,255 which was consistent with other published data in Northern 
European populations.256,257 Contrary to the others, Torok et al reported associations 
with colonic disease, non-fistulizing non-fibrostenotic disease and reduced need for 
surgery.258 This illustrates the difficulty in identification of the causal variants due to 
the strong linkage disequilibrium across the IBD5 region, which includes a number of 
other candidate genes coding for proteins that are involved in immune processes (e.g. 
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IRF1 (interferon regulatory factor-1), IL-3, IL-4, IL-5 and CSF2 (colony stimulating 
factor 2). 
 
In paper I we set out to study genotype-phenotype correlations regarding 
NOD2/CARD15 polymorphisms and CD in children. Due to the low prevalence this 
was not possible, but a number of studies have confirmed the association of these 
polymorphisms with ileal, stricturing and penetrating disease, especially in compound 
heterozygotes or homozygotes.50,55,66,68 Ogura et al reported that NOD2/CARD15 
linked to ileal disease, through its high expression in Paneth cells in the ileum and its 
weak expression in the colon.74 We noted a trend towards granulomas being more 
frequently found in NOD2/CARD15 positive patients (p =0.17), and larger studies have 
reported such association with statistical significance.50,68,259 This would be in line with 
the hypothesis that granulomas are formed as a result of defect clearance of 
microorganisms179,180and the suggested negative effects on the immune defense from 
NOD2/CARD15 aberrations.  
 
6.2 DISEASE LOCATION 
Interestingly, in Sweden the CD patients have a low prevalence of the NOD2/CARD15 
polymorphisms but also, according to the results in papers I, II and IV, relatively low 
frequency of ileal disease, especially isolated ileal disease, and rather high frequency of 
isolated colonic disease. An increase in pediatric colonic CD in Stockholm was noted 
already in a paper in 2003 by Hildebrand et al.13 The disease distribution at onset in 
pediatric CD in a number of reference papers are shown in Table 10. Colonic 
involvement was present in 58-92%, ileal involvement in 62-90%, isolated ileal disease 
in 6-37%, and isolated colonic disease in 7-38% of the patients.  
 
Comparison between studies regarding the distribution of the disease at onset is hard, 
because the results depend on how the patients were investigated (colonoscopy with or 
without ileum intubation), whether the assessment was made on macroscopic and/or 
microscopic findings, whether radiology was included, what type of center that was 
performing the study and how the selection of patients was performed. One can argue 
that the relatively low frequency of ileal involvement reported in our studies depends 
on the lack of a full work-up (i.e. endoscopy including ileum intubation and biopsies). 
To overcome this we extracted the patients in paper IV who had an endoscopic ileum 
investigation at diagnosis and found the same distribution of the disease; 5% had 
isolated ileal disease, 50% had isolated colonic disease and 45% had ileocolonic 
disease.  
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Table 10. Disease distribution at diagnosis in pediatric Crohn´s disease.
Study  Country  Age at 
diagnosis
L1
 
L2
 
L3 
 
Freeman, 2004 233   Canada  <20 y
 
21% 21% 57%
Griffiths, 2004 11  Canada  <17 y
 
36% 20% 42%
Mamula et al, 2002 203  USA  <5 y
 
11% 30% 59%
Heyman et al, 2005 193  USA  <6 y 
 
32%  
Heyman et al, 2005 193  USA  6‐12 y
13‐17 y 
20%
24% 
 
Paul et al, 2006 204  USA  <5 y
 
76% 24%
Paul et al, 2006 204   USA  <16 y
 
24% 29% 47%
Kugathasan et al, 2003 157  USA  < 18 y
 
25% 32% 29%
Levine et al, 2007 262  USA, Italy, Israel <17y 
 
21% 25% 54%
Levine et al, 2007 262  USA, Italy, Israel <10 y
            
NOD2 neg. 48%  
NOD2 pos. 20% 
 
Levine et al, 2007 262  USA, Italy, Israel >10 y
            
NOD2 neg. 25%  
NOD2 pos. 14% 
 
Sawczenko et al, 2003 154  UK  <16 y
 
9% 7% >80%
Van Limbergen et al, 
2008 155 
Scottland  <17 y
 
6% 36% 51%
Auvin et al, 2005 202  France  <17 y
 
19% 10% 71%
Vernier‐Massouille et al, 
2008 156 
France  <17 y
 
14% 17% 69%
Pigneur et al, 2010 230  France  <16 y
  
37% 26% 36%
Perminow et al, 2009 200 Norway  <18 y
 
8% 23% 69%
Jakobsen et al, 2011 253 Denmark  <15 y
 
21% 38% 41%
Pediatric CD, range 
(subgroups excluded) 
  6‐37% 7‐38% 29%‐80%
Ideström et al, Paper IV
 
Sweden  <17 y 5% 50% 45%
Disease distribution; L1= isolated ileal, L2= isolated colonic and L3= ileocolonic disease       y =years 
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One can speculate whether colonic disease is more common also in adult CD in 
northern countries as both a Swedish and a Danish population-based study on adult CD 
found an increased colonic phenotype (>50%)260,261 and, in line, a recent population-
based Danish study found isolated colonic localization in 48% of adults with CD.253 
Riis et al compared disease characteristics in adult CD between North and South 
European centers, but found no statistically significant difference regarding gender, 
age, disease location or behaviour at time of diagnosis, although isolated colonic 
disease was most frequent in Norway (41.9%), Denmark (41.4%) and the Netherlands 
(41.5%).245 
   
In paper II we showed that ileal disease is age dependent and that it occurs rarely before 
the age of 9. When ileal disease is present, it is most often associated with colonic 
disease. We also showed that the probability of ileal disease increases with age until 
puberty and/or adulthood. These findings in paper II, as well as findings regarding 
disease distribution and NOD2/CARD15 polymorphisms in papers I and IV, are 
consistent with other reports on less ileal disease and more colonic disease in patients 
younger than 5-6 years193,203,204 and an association between isolated colitis in CD at 
young age (<10 years) and absence of NOD2/CARD15 polymorphisms262 (also shown 
in Table 10). Our finding of age- dependent ileal involvement supports the hypothesis 
that the Peyer´s patches (PPs) and the isolated lymphoid follicles are potential sites for 
CD lesions. While the colonic isolated lymphoid follicles do not vary with age, the ileal 
PPs develop early in fetal life, grow in size and number until puberty, and then undergo 
involution.125,126 As a result, the ratio ileitis/colitis should be lower in young children, 
as shown in our study, and in seniors, which is supported by reports on less ileal 
involvement in seniors than in young adults.30 
 
6.3 GROWTH 
Growth impairment is regarded as a prominent feature of CD in children, although 
studies in pediatric CD report a great variety on the prevalence of growth impairment. 
Not all have used the same definition of growth impairment, or considered the 
influence of the patients´ age, pubertal stage or target height. Target height is 
considered the best predictor for final height263 and it is, therefore, advisable to evaluate 
final height as well as height at diagnosis after adjusting for target height. In paper IV 
we did adjustments of both height at diagnosis and final height to target height, and we 
also extracted a subgroup of children younger than 10 years to rule out the influence of 
puberty. Interestingly, the patients in paper IV were not growth impaired, neither at 
onset nor as adults. The absence of growth impairment is congruent with the current 
trend towards lower frequencies of growth impaired children with CD209 but differs 
from other studies reporting impaired final height.208,264  
 
The normal growth and attainment of expected final height among our patients during 
the course of their disease may be explained by fact that the children were not growth 
impaired at diagnosis, but an early use of enteral nutrition, lesser use of corticosteroids, 
a frequent use and early start of immune modulating agents and TNF-α blockers might 
also be contributing reasons. The absence of growth impairment at the time of 
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diagnosis seems more difficult to explain, since that is dependent on factors unrelated 
to treatment modalities. We speculate that a general awareness among referring 
colleagues and an easily accessible health care may have contributed to the short 
duration of symptoms before diagnosis (median 3.4 months). Since colonic and not 
small bowel disease prevailed among the children, the prominent symptoms caused by 
colitis may have contributed to symptoms prompting to seek medical care with less 
delay. Both longer delay and small bowel disease are known from other studies to be 
associated to growth impairment.96,154,265 
 
Normal growth is dependent on hormones, of which growth hormone acting through 
IGF-I is of great importance. The actions of IGF-I are modulated by IGF binding 
proteins, mainly IGFBP-3, which affects the availability of IGF-I in the circulation. 
Undernutrition depresses IGF-I and growth failure in children with CD has therefore 
been attributed to poor nutrient intake. However, animal work (on TNBS colitis) has 
shown that the inflammatory process depressed growth and IGF-I partly independently 
of nutrition and that it was characterized by elevated IL-6 levels.241  
 
The severity of growth impairment in individual patients does not always correlate to 
the level of intestinal inflammation as assessed by symptoms, raising the speculation 
that genetic polymorphisms might influence growth patterns. However, the difficulty 
and lack of consistency in defining growth impairment, makes analyses of correlation 
of growth impairment with genotype almost impossible in large scale studies. In paper 
III we have strengthened the hypothesis that common genetic polymorphisms which 
alter cytokine expression may contribute to growth impairment, but not influence the 
overall susceptibility to CD. In the animal studies in paper III, using the TNBS colitis 
model, we demonstrated that blocking the effect of IL-6 enhances growth, not through 
reduced intestinal inflammation or improved nutrient intake, but directly through the 
decrease in circulating IL-6. With the finding that IL-6 may regulate growth in 
inflammatory diseases, we hypothesized that genetic variations in IL-6 expression 
would influence the consequences of disease activity on growth retardation. We studied 
the IL6 -174 polymorphism because variations in this region of the IL6 promoter are 
associated with variations in the IL-6 response243 and found that the IL6 -174 genotype 
determines growth retardation at diagnosis in childhood onset CD. There was no 
difference in genotype distribution between the children with CD and the controls 
indicating that the IL6 -174 genotype was not associated with the disease itself, which 
is in agreement with previous and later reports.48,266,267 Other studies have also shown 
that there is no correlation between haplotype and short stature among healthy people 
in whom the promoter would have been inactive.268 However, the IL6 -174 promoter 
has been shown to be important as a disease modifying gene, influencing not only 
growth but also disease location (i.e. the GG haplotype associated with ileocolonic 
disease and the CC haplotype associated with isolated colonic disease)269 and age at 
onset (i.e. younger age at onset in males with the GG haplotype).267 
 
Similarly to our data regarding the IL6 promoter polymorphisms, a study of Israeli 
patients suggests that relatively common variations in the promoter region of the TNF-
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α gene may have an independent effect on linear growth outcomes.96 NOD2/CARD15 
gene polymorphisms have not been associated with growth retardation or growth 
failure.207 Lower weight and a trend towards reduced height was found by Tomer et al, 
although this finding may rather be secondary to the association between 
NOD2/CARD15 gene variants and ileal disease.244 
 
Growth sparing treatment should be a priority in children with the IL6 -174 GG 
genotype, as well as in all children with growth failure. One example of such treatment 
is EEN, which is already used as primary treatment for CD in children.174,190 EEN 
results in a rapid fall in IL-6 and an increase in circulating IGF-I.222 IL-6 blocking 
treatment has not been studied in children with growth or height as an endpoint, but 
results in a trial on adult CD (n=36) showed some clinical effects, but there were no 
endoscopic or histological differences compared with placebo.270 
 
6.4 COMPLICATIONS AND SURGERY 
According to previous long-time follow-up studies, disease behaviour rather than 
location show progression with time in pediatric and adult CD.155,156,229 In paper IV we 
followed a cohort of 45 pediatric CD patients for 9 to 18 years, median 12.3 years, 
which is ample time to observe changes in disease behaviour, for complications to 
appear, and to monitor medical and surgical treatments. The majority (80%) of the 
patients (n=36) still had non-stricturing, non-penetrating disease at follow-up but 20% 
had developed strictures. Vernier-Massouille et al reported that only 41% of the 
children had non-stricturing, non-penetrating disease at 10 years follow-up and 44% 
had actually developed stricturing disease.156 Pigneur et al reported that 25% of the 
pediatric patients had stricturing disease after 10 years,230 and Freeman et al found 
strictures in 29% after median follow-up of 12.2 years.233 The differences in 
complication rates may reflect differences in disease location as stricturing disease 
behaviour has been found associated to ileal and jejunal disease.155,229 Risk for surgery 
is also associated with stricturing and/or penetrating disease as well as ileal or 
ileocolonic, rather than colonic disease.233,271 Strictures, abscesses/fistulas and surgery 
are also associated with older age within pediatric CD (>13 years),232,271 which may be 
an effect of the age influencing the location. The relatively low incidence of small 
bowel involvement in our studies (paper I, II and IV) might be a factor influencing the 
low number of complications in terms of internal fistulas, strictures and the frequency 
of surgery. We found that surgery had been performed in 22% of the patients in total 
and in 9% within the first 5 years (paper IV), which is somewhat lower compared to 
other pediatric studies of CD that has reported surgery in 28-60% after >10 years of 
follow-up230,232,233 and 14-34%  after 5 years of disease.156,232,253,271 Our findings are in 
line with the results of Picco et al which indicate that disease limited to colon is 
associated with less surgery234 and the results of Schaefer et al which show a decreased 
risk of surgery when colon was involved.271 Of course, reluctance to surgery in young 
CD patients and a different treatment policy in our unit compared to others may also 
have played a role for the relatively low number of patients that had undergone surgery.  
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6.5 TREATMENT AND DISEASE MODIFICATION 
Although the treatment goal, to achieve and maintain remission, normal growth and 
puberty as well as a good quality of life, is well accepted regarding pediatric CD, the 
choice of strategy to reach the goal may be discussed. On one hand the treatment needs 
to be safe and cause as little negative side-effects as possible, on the other hand it must 
be effective and if possible protect the child with CD from complications. We generally 
use a step up treatment strategy, but there is an increasing awareness of the need of 
early immune modulating treatment in subgroups of patients.174  
 
In paper IV we noticed that a large proportion of the patients (76%) were treated with 
immune modulating agents and almost half of them were started on such treatment 
during the first year of illness. It has been shown that surgical treatment is less frequent 
among patients treated with immune modulators or TNF-α blockers, compared to those 
without such treatment232,234,272 and the time to initiation of immune modulators was 
shorter in a non-surgery group compared to patients who underwent surgical 
treatment.156 In our data in paper IV we could only trace a similar trend, as the time to 
the first surgical procedure was longer in patients who were treated with immune 
modulators or TNF-α blockers compared to those who did not receive such treatment, 
although the low number of patients in the surgery group makes these results 
unreliable.  
 
The effects of specific treatments on the rate of surgery often become speculative due 
to limitations of the design of the previous studies. More aggressive treatment may 
reflect a worse disease course, which makes it difficult to interpret the results. Even 
though the use of immune modulating agents (i.e. thiopurins or methotrexate) has 
increased over a period of time and is initiated earlier during the disease course, Cosnes 
et al found that the frequency of stricturing and perforating complications, as well as 
the need for intestinal resections, have remained stable over 25 years.273 However, the 
limitations of that study are important to consider. It was a retrospective study from a 
tertiary referral center (generally treating patients with severe CD) and very few (8.4%) 
of the surgical patients had azathioprine prior to surgery, which may be the reason for 
the need of surgery and probably azathioprine was initiated too late in their disease 
course to prevent stricture or fistula formation. Benchimol et al showed that treatment 
changes in children with CD between 1994-2007 (including increased 
immunomodulator use and increased outpatient care by pediatric gastroenterologists) 
were associated with reduced surgical rates274 and Ramadas et al also found decreasing 
surgical rates associated with increased and earlier thiopurine use over time (1998 to 
2003).272 
 
The potential for disease modification in CD, by various therapeutic interventions is 
discussed further in a recent review by Van Assche et al.275 It was concluded that one 
surrogate marker of disease modification is the healing of CD lesions, since the 
mucosal lesions reflect ongoing inflammation and tissue damage, which in turn lead to 
fistulas, abscesses, adhesions and strictures and thereby also surgery. Nevertheless, no 
prospective long-term trial has studied the value of mucosal healing to predict a 
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decreased need for surgery or hospitalization as the primary outcome, and it has not yet 
been convincingly demonstrated that mucosal healing also means a turn off of deeper 
inflammation.  
 
Both thiopurines and anti-TNF-α agents have shown potential of inducing mucosal 
healing. The time point at which the initiation of therapy takes place is of great 
importance, as the longer the disease is left untreated the more irreversible the damage 
will be. There is evidence from pediatric IBD that more aggressive treatment early in 
the disease course is associated with improved response and remission rates.276-279 
Indirect evidence that early aggressive treatment may induce profound remission are 
the results from a study on step up verses top down treatment strategy on newly 
diagnosed CD by D’Haens et al where the top down approach included induction 
therapy with infliximab and azathioprine. After two years, complete mucosal healing 
was observed in 75% of patients in the top down group compared with only 21% of 
patients in the step up treatment group. The top down group continued on episodic 
infliximab treatment with a median of 16 weeks between infusions, as compared to 8 
weeks in the step up group.280 
 
Anti-TNF-α agents are proven to be an effective maintenance therapy for pediatric CD, 
but a problem is that a substantial number of patients lose initial response, and 
adjustments in the treatment schedule (i.e. dose escalation, reduction in dose interval, or 
both) are frequently needed to maintain clinical remission.281,282 In adult CD, a 
combination of azathioprine and inflixmab has been shown to be more effective than 
monotherapy of either agent.283 Studies on the potential benefit of combination therapy 
in children are limited and due to a possibly increased risk of toxicity in children on 
combination therapy, we presently convert from combination therapy to monotherapy 
within 6 months (or combine the anti-TNF-α agent with methotrexate). 
 
Accordingly, more prospective intervention studies in newly diagnosed patients, 
preferably large randomized controlled studies, will be needed to evaluate the effects 
on disease course by different agents and strategies. 
 
It is of great importance to weigh the probable benefit of more and early aggressive 
therapy against the disadvantages and potential risks (i.e. mainly increased rates of 
infections and malignancies) associated with such treatment, especially in children who 
have many years on medication ahead. Patients with IBD have an increased risk of 
opportunistic infections and especially patients on a combination of more than one 
immunomodulator and those with malnutrition.284 Regarding anti-TNF-α treatment in 
children, pooling of pediatric IBD studies shows serious or unusual infections in 
approximately 3% of patients treated with infliximab (n=1483) or adalimumab  
(n=237) (e.g. sepsis, Listeria monocytogenes meningitis, herpes zoster or varicella 
infections, reactivation of Epstein–Barr virus, pneumonia, abscesses, cutaneous tinea 
infections, opportunistic fungal infection, osteomyelitis, cellulitis, Pseudomonas 
infection, pseudomembranous colitis, gastroenteritis, appendicitis and pancreatitis).285 
Other rare events in CD are hemophagocytic lymphohistiocytosis (HLH), 
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histoplasmosis and disseminated cytomegalovirus. Studies in adult IBD on the risk of 
developing malignancies when treated with thiopurines and/or TNF-α blockers have 
shown conflicting results. However, a meta-analysis showed a fourfold increased risk 
of lymphoma in IBD patients treated with thiopurines286 and another meta-analysis on 
adult CD patients demonstrated that use of anti-TNF-α drugs in addition with 
immunomodulators was associated with a threefold increased risk of non-Hodgkin’s 
lymphoma.287 In young IBD patients treated with anti-TNF-α and/or thiopurines, a 
serious and extremely aggressive type of lymphoma, hepatosplenic T cell lymphoma 
(HSTCL), has been reported227 and the rates for malignancies in anti-TNF-α treated 
children (with various diagnoses) in USA were higher than in the general US pediatric 
population.288 It is currently not known whether the development of malignancies, or 
the other rare events previously mentioned, is related to the severity and chronicity of 
the inflammation, to the long term use of immunosuppressants, or to a combination of 
both. 
 
Finally, mucosal healing in a larger proportion of patients could of course have 
additional advantages in terms of quality-of-life of our patients and cost for society, 
assuming that surgery, hospitalization and open clinic consultations for flare-ups are 
expensive, and thereto added the costs of sick leave and disability, but a possible 
downside of for example earlier anti-TNF-α therapy may be the increased cost of the 
drug, added to the risks of infections and malignancies. We do not yet know who would 
benefit the most from early aggressive (top down) treatment because of lack of reliable 
predictors, and one should keep in mind that a large proportion of the patients in fact 
have a disease remission state over time,239,289 which means that having anti-TNF-α 
agents as the first-line therapy would correspond to an overtreatment for many CD 
patients. 
 
6.6 MARKERS FOR PREDICTING DISEASE COURSE 
Several previous studies on both adult and pediatric CD have investigated which 
clinical variables are associated to complicated disease course, most often defined as 
need for surgery, progression towards non-inflammatory disease behaviour, relapse 
frequency and steroid dependency. In paper IV we used growth impairment, immune 
modulating (including thiopurines and methotrexate) and TNF-α blocking treatment, as 
well as surgical interventions as surrogate markers for severe disease. 
 
Disease location as a risk factor has already been discussed; small bowel disease is 
associated to higher risk of complications such as strictures, fistulas, surgical 
procedures and growth impairment, and since age influences the disease location (paper 
II), older age within the pediatric population may in that sense be regarded as a risk 
factor. Involvement of upper GI tract has been found associated to higher surgery 
risk239 and is a predictive factor for disease recurrence.289 Lower age at diagnosis and 
coexisting upper GI tract involvement have been found significantly associated with 
steroid dependency in children with CD.290 Lack of mucosal healing after induction 
therapy has also been proposed to be a predictor of aggressive disease course including 
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greater disease activity and an increased need for medical treatment.291,292 Current 
smoking has already been mentioned as a risk factor for developing CD and is 
associated with higher recurrence rates and increased risk for surgery. 
 
In paper IV we studied the significance of granuloma findings and conclude that 
presence of granulomas at onset may be a marker for a more severe disease. Why some 
patients, preferably children, form granulomas, and others do not, probably has to do 
with the function of the immune system and the possible underlying genetic 
aberrations. Perminov et al found an increased frequency of mucosal macrophages, 
together with an elevated activation level (e.g. CD40 expression), especially in the 
colon of untreated CD children, which might explain the colonic phenotype and the 
increased numbers of granulomas in pediatric CD.293 The vast majority of the 
granuloma findings in paper IV were done in biopsies from colon in agreement with 
previous studies stating that the frequency of granulomas gradually becomes higher 
more distally along the GI tract.201,294,295 One could suspect that the formation of 
granulomas is associated with variants in ATG16L1 and IRGM genes, which are 
believed to affect the autophagy pathways and give rise to impaired pathogen clearance 
in the cell, but variants in these genes have not shown any significant association with 
granulomas.296 The possible association between granulomas and NOD2/CARD15 
polymorphisms is discussed above, whereas studies on known genetic variants in TLR4 
and TNF-α genes did not show associations with granulomas.295,297 
   
Granuloma findings at diagnosis were found to be associated to upper GI involvement 
and earlier initiation of immune modulating agents in children with CD in paper IV. 
We interpreted this as these children were having more extensive disease and a need of 
more aggressive treatment and thus having a more severe disease. Other studies have 
indeed shown associations between granulomas and complicated or severe disease.195-
199,298-300 Markowith et al noted that pediatric patients with granulomas in the initial 
rectosigmoid biopsies more often had extensive disease, perianal complications and 
surgical interventions.299 Molnar et al, as well as Freeman et al, found associations 
between granulomas and complicated disease behaviour, especially penetrating and 
extensive disease with upper GI localization, also requiring more surgical interventions, 
hospitalizations and immunosuppressive treatment.195,199 De Matos et al found an 
association between granulomas in initial biopsies in children and perianal disease, 
gastritis and infliximab treatment.196 Recurrence after surgery is the most studied 
outcome and a recent meta-analysis on studies mainly in adults showed significantly 
higher rates of recurrences and reoperations in the granulomatous group compared to 
the non-granulomatous group.300 On the other hand, there are other clinical studies that 
did not confirm an association between granulomas and a more complicated disease 
phenotype.294,301,302 Gupta et al even found that granulomas were inversely associated 
with risk for surgery.232 
 
In a recent review, Kaser et al speculate that the subset of patients which exhibit 
granulomas, seen as the pathologic hallmark of IFN-γ expression, may benefit from 
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INF-γ blockade,303 although such blockade has showed limited efficacy in human IBD 
(compared to a positive effect in murine experimental colitis).304   
 
The rapid development in the area of genetics is of course promising when it comes to 
the ability to subgroup the patients regarding their genotypes and further on hopefully 
foresee the phenotypes and prognosis of the disease. Today we can generally only state 
what clinical features that are statistically associated to different genetic alterations, and 
not forecast which patients that will develop a specific complication.  
 
The prognostic power of NOD2/CARD15 alterations has been studied in a recent meta-
analysis.305 The presence of a single NOD2/CARD15 variant had poor predictive ability 
for disease phenotype in CD. However, the presence of two variant alleles in 
NOD2/CARD15 (either homozygous or complex heterozygous) was associated with a 
relative risk of 1.44, with a high degree of specificity (98%) for aggressive disease 
phenotype, although the sensitivity was poor (11%). The presence of homozygosity for 
Leu1007fs had an even higher degree of specificity for aggressive disease phenotype, 
although the sensitivity remained poor.305 Thus testing for double dose variant alleles 
could identify a particularly high-risk group, where targeted early-intensive therapy 
might be beneficial, although it is a very insensitive prognostic test and would likely 
miss many patients with aggressive disease. In populations with low prevalence of the 
CD associated NOD2/CARD15 variants, as in Sweden, such testing would rarely add 
helpful information. 
 
The IL6 -174 genotype mediates growth failure in children with CD. As suggested in 
paper III, growth promoting treatment should be a priority in children with the IL6 -174 
GG genotype. Since IL-6 is central in many inflammatory conditions, our findings 
could be relevant for growth impairment in other such diseases in childhood. The IL6 
genotype may also influence other clinical aspects of the disease, as discussed above, 
but whether different haplotypes of the IL6 gene hold prognostic power for disease 
phenotype has not yet been evaluated. 
 
Several immune-mediated antibodies against microbial antigens have been described in 
IBD and the most studied antibodies are perinuclear antineutrophil cytoplasmic 
antibody (pANCA), anti–Saccharomyces cerevisiae antibody (ASCA), antibody to the 
outer membrane porin of Escherichia coli (anti-OmpC), antibody against flagellin 
expressed by Clostridial phylum (anti-CBir1), anti–chitobioside carbohydrate antibody 
(ACCA), anti–laminaribioside carbohydrate antibody (ALCA), and anti–mannobioside  
carbohydrate antibody (AMCA).306 Evidence suggests that these serologic markers can 
help to establish a diagnosis of IBD and to differentiate CD from UC, particularly when 
used in combination.307 and in CD, multiple studies have linked the presence of 
antibodies to more complicated disease, including fibrostenosis, internal penetrating 
disease, as well as increased need for surgical interventions involving the small 
bowel.306 Moreover, it seems that having multiple positive serologies or high titers 
predicts poor outcome. Dubinsky et al examined how the degree of immune response 
to ASCA, anti-OmpC, and anti-CBir1 correlated with internal penetrating and 
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stricturing disease and the need for surgery in a large pediatric CD cohort, and they 
showed that the risk for the development of complicated CD was higher among patients 
positive for three of these antibodies compared to those positive only for two or less.308  
 
Fecal calprotectin has been suggested to be useful marker for predicting the disease 
course in a shorter perspective, i.e. predicting disease relapse within the coming months 
or years (depending on the study) in both adult and pediatric IBD. Cut-off values of 
250-400 μg/g have been proposed to predict a coming relapse in patients in clinical 
remission.309-311 A recent meta-analysis stated that fecal calprotectin is useful to predict 
relapse in quiescent IBD patients and the pooled sensitivity and specificity of predicting 
relapse was 78% and 73%, respectively.312 Fecal calprotectin has also been studied as a 
prognostic marker for outcome after induction treatment with TNF-α blocking agents 
in adult luminal IBD, and a cutoff concentration of 139 μg/g had a sensitivity of 72% 
and a specificity of 80% to predict a risk of relapse within 1 year, and a normal fecal 
calprotectin after induction therapy with a TNF-α blocker predicts sustained clinical 
remission in the majority of patients on scheduled therapy.313 Fecal calprotectin has 
been shown to reflect the degree of microscopic inflammation,163 thus these results are 
all in line with the advantages of mucosal healing discussed above.  
 
Due to the complex pathophysiology of CD and the heterogeneity of the phenotype, it 
is important to combine genetic, clinical and serologic information into predictive 
models for disease course and treatment response. Panels that incorporate multiple 
genetic loci and/or multiple serologic markers have been presented and more will likely 
develop further over the next few years.314-317 Future studies dealing with prognostic 
markers will require large-scale, multicenter trials to find sufficient clinical data to 
accurately determine the cumulative risk of clinical, serologic, genetic, and 
environmental factors. The importance of uniformed diagnostic work-ups, diagnostic 
criteria and phenotypic classifications cannot be stressed too much and accordingly 
ESPGHAN has defined the criteria for pediatric IBD159 and now the EUROKIDS 
registry collects prospective data on pediatric IBD from 17 European countries.165 It 
would also be of interest to use well defined sub-phenotypes, such as treatment 
responders/non-responders and defined geographic areas, to understand possible 
differences between CD in various countries as well as ethnical groups. When 
additional predictive factors are identified and validated, predictive models will 
hopefully become powerful tools that can be used in the clinical setting and then we 
will be better able to study targeted therapies in high-risk patients. The ultimate goal is 
to treat the individual patient with the most suitable agent, with the optimal timing and 
with minimized risks, to improve prognosis and quality of life. 
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7 CONCLUSIONS 
The following conclusions can be drawn from the studies presented: 
 
¾ Pediatric Crohn´s disease in our patient cohort is dominated by more colonic 
disease and less ileal involvement (paper I and IV) 
 
¾ Growth impairment is infrequent in our patient cohort of pediatric CD, both at 
onset and at follow-up (paper IV) 
 
¾ NOD2/CARD15 polymorphisms are uncommon in Swedish pediatric CD 
(paper I) 
 
¾ Ileal involvement seldom occurs before the age of nine years and the 
probability of ileal disease increases with age until adulthood (paper II) 
 
¾ Isolated ileitis is rarely found in pediatric CD and ileal involvement is often 
associated with colonic disease (paper II) 
 
¾ IL-6 causes growth suppression in rats with TNBS colitis and by blocking IL-6 
with antibodies the IGF-I levels are increased and growth is enhanced, without 
improving the intestinal inflammation or increasing the food intake (paper III) 
 
¾ Children with CD that have the IL6 -174 GG genotype have higher CRP levels 
during active disease and are more growth-retarded at diagnosis, indicating a 
negative influence from a higher expression of IL-6  in patients with the GG 
haplotype (paper III) 
 
¾ Epithelioid cell granulomas are found in half of the pediatric CD patients at 
onset and are associated with both upper GI involvement and a shorter time to 
initiating immune modulating drugs, suggesting an association with a more 
aggressive disease (paper IV) 
 
¾ Final length is not negatively affected by findings of granulomas at CD 
diagnosis (paper IV) 
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8 FUTURE PERSPECTIVES 
The advances in the fields of genetics and immunology have enhanced our knowledge 
and understanding of the pathophysiology and etiology of CD. For many of the genetic 
loci that are associated with CD potentially causal genes have been identified.48 For 
confirmation of their role, detailed fine mapping as well as expression and functional 
studies are necessary. An important future goal is to find evidence of sub-phenotype 
associations, both related to disease behaviour to predict disease course, and to 
response to various treatment options. A successful example from another area is the 
identification of a genetic variant in the IL28B gene that is associated with response to 
anti-hepatitis C virus treatment and the natural clearance of a hepatitis C virus.318,319 
 
To be able to find associations with genetic variants with lower allele frequencies 
and/or in smaller phenotypic subgroups, the studies have to be large. This is especially 
challenging when studying individuals from certain geographical areas or with specific 
ethnic background, as well as children, since these study populations are smaller. 
 
A strategy to obtain large-scale fine mapping studies is to use custom array-based 
technologies. Underway is the Immunochip project of the International IBD Genetics 
Consortium where a custom designed chip with 200 000 markers is to be studied on 15 
000 CD patients, 12 000 UC patients, 21 000 healthy controls and 100 000 samples 
from other immune-mediated conditions.320  
 
As discussed above, it is of great importance to have uniform diagnostic work-ups, 
diagnostic criteria and detailed phenotypic classifications, as well as to combine 
genetic, clinical and serologic information to be able to predict disease course and 
treatment response. The influence from the environment must also be taken into 
account and in the future an integration of epigenetic data obtained from micro-RNA 
profiles will also be useful. (Epigenetics refers to modifications of the genome that 
have functional effects, but does not involve changes in the nucleotide sequence of the 
DNA).  
 
The growing field of transcriptomics, referred to as expression profiling, may hold 
potential in terms of refining the diagnostic and prognostic information in IBD. Tools 
that allow measurements of genome-wide RNA from the peripheral blood and tissue of 
patients can result in gene expression profiles that may predict prognosis. For example, 
a recent study identified a gene expression profile from peripheral blood T cells that 
was associated with a more severe disease course of IBD321 and another study 
demonstrated the role of gene expression profiles (in biopsies) in predicting response to 
TNF-α therapy in colonic CD.322 
 
Several times in this thesis it has been stated that relevant prognostic markers would be 
very useful when selecting patients for early aggressive treatment, to avoid both over-
treatment accompanied with the risk of unnecessary side-effects and under-treatment 
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with the risk of irreversible complications of the disease. Of importance is of course to 
know not only at what time point a certain treatment should be initiated but also which 
treatment is the most suitable for each individual. Further genotyping may also give the 
potential for sub-classification of the disease regarding the dominating disease causing 
alterations and impairments of the immune response in the individual, and this would 
give us the possibility to use more targeted therapy. One example could be the 
autophagy dysfunction, which is thought to be an important mechanism in the 
pathogenesis in CD following the alterations in several genes involved in autophagy 
(e.g. ATG16L1 and IRGM) that have been found to be associated with CD. Since there 
are agents already known to either upregulate autophagy (rapamycin, lithium) or inhibit 
it (quinine, valproate) this could theoretically be a treatment option for selected 
individuals.323  
 
Most of the therapeutic agents used in CD today are aiming at dampening the immune 
response. The individuals in whom future screening may reveal an impaired innate 
immune defense as the dominating underlying cause would perhaps instead benefit 
from immunostimulating treatment. One example of such treatment is the granulocyte-
macrophage colony stimulating factor which has shown therapeutic effect in 
(congenital) phagocyte disorders. Clinical trials of recombinant granulocyte-
macrophage colony stimulating factor (Sargramostim) have been performed in CD 
patients, with positive effects in some patients,324-327 although large, randomized trials 
have failed to reach primary clinical end points,325 suggesting that alterations in 
granulocyte-macrophage colony stimulating factor function may be linked only to 
subsets of IBD.328 This is supported by studies that have reported neutralizing 
autoantibodies to granulocyte-macrophage colony stimulating factor in subsets of 
pediatric and adult CD patients329 and defective expression and function of the 
granulocyte-macrophage colony-stimulating factor receptor among IBD patients.330  
 
Several new biologic agents have been tested or are under development (e.g. anti-IL-
12/23, anti-IL-17, IL-6 inhibitors, anti-IFN-γ and antibodies blocking adhesion 
molecules or chemokines) and even though none have yet proved superior to anti- 
TNF-α331 they might have to be re-evaluated when using specific sub-populations,332 
higher doses or different ways of drug administration.  
 
Another way of targeting the treatment would be to deliver potent therapeutic agents 
directly to the sites of inflammation in the GI tract. Trials with engineered enteric 
bacteria, which produce and secrete the anti-inflammatory cytokine IL-10, have been 
performed in CD, but the efficacy is unclear.333 Using a nonreplicating adenoviral 
vector for IL-10 expression in colon has shown positive effects in IL-10 knock-out 
mice334 but there are safety concerns regarding the use of viral vectors in humans. 
Instead, a nonviral method of gene transfer would be preferred. For example, 
nonoparticles can be designed to concentrate in the target tissue and deliver the 
therapeutic agents.335 Hopefully, the increasing knowledge in the field of nanomedicine 
will lead to progress regarding treatment of IBD in humans.336 
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Stem cell therapy for intestinal diseases is also an emerging area. Although clinical 
remission of IBD has been reported in patients who were treated with autologous (i.e. 
originating from the recipient) or allogeneic (i.e. originating from a donor) 
hematopoietic stem cell transplantation for coincidental malignancies, the risks 
accompanied with the long term immunosuppressive treatment and risk of graft versus 
host disease, are seldom outweighed by the benefits. However, there are reports on 
autologous stem cell therapy as salvage therapy for IBD and a multicenter, prospective, 
randomized, phase III trial (ASTIC trial) is supposed to report the initial analyses 
within a year.337,338 There are also sporadic reports on successful allogeneic bone 
marrow stem cell transplantation in cases with well defined underlying genetic 
mutations, such as in the gene encoding the IL-10 receptor,339 and in which autologous 
stem cell transplant would not alter the underlying genetic polymorphism. 
 
Mesenchymal stem cells have clear advantages due to their immunosuppressive 
capacity and they have been tested in several preclinical models for the treatment of 
IBD and, subsequently, in a few clinical trials. Injected mesenchymal stem cells are 
believed to home to areas of injury where they have reparative functions and/or act as a 
source of secreted factors that stimulate repair and inhibit inflammation. These 
multipotent progenitor cells can be isolated from a variety of tissues and can 
differentiate into many different cell types.340 They were earlier thought to be ‘non-
immunogenic’, however, it is now known that these cells are detected by the immune 
system of the recipient which results in the clearance of the injected cells.341 One small 
study on autologous mesenchymal stem cells, given to patients with active and 
treatment refractory CD, reported clinical improvement in 3/7 patients.342 A larger, 
randomized, placebo controlled, double-blind Phase III study on a allogeneic 
mesenchymal stem cell product derived from healthy donors (Prochymal brand of 
remestemcel-L) for CD was begun in 2007 and is still ongoing.343,344 Local injections of 
autologous mesenchymal stem cells have shown efficacy in fistulizing CD.345-347 
Further research is needed in this area to answer a number of questions regarding 
safety, efficacy, mechanism, the optimal dose and way of administration (systemic, 
local injection or topical application) and usage (as inductive and/or maintenance 
therapy) of mesenchymal stem cell therapy in CD. 
 
There is exciting and challenging future research to be done to further identify the 
etiology of CD and its pathophysiology. The heterogeneity in disease genotype and 
phenotype, as well as disease outcome and prognosis, has to be especially addressed 
when aiming towards individualized treatment, which hopefully may direct the disease 
course in the desired way. 
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9 SAMMANFATTNING PÅ SVENSKA 
Förkortningen IBD (efter engelskans ”inflammatory bowel disease”) används som 
samlingsnamn för huvudsakligen två kroniska inflammatoriska tarmsjukdomar; ulcerös 
kolit och Crohns sjukdom. Till skillnad från ulcerös kolit som endast involverar 
tjocktarmen, kan Crohns sjukdom vara lokaliserad var som helst längs mag-
tarmkanalen, från munhålan till anus. Sjukdomsstart sker oftast i tonåren eller i ung 
vuxen ålder, men även små barn kan drabbas. I Sverige insjuknar upp emot 200 barn 
(under 16 år) varje år i IBD, 2/3 av dessa får diagnosen Crohns sjukdom. Vanliga 
symtom är buksmärtor, diarré, blod och slem i avföringen, viktnedgång och försämrad 
längdtillväxt. Vissa har, eller får, komplicerande s.k. fistlar eller bölder kring anus, 
förträngningar på tarmen (stenoser) eller påverkan på andra organ så som lever, 
gallvägar, leder, hud eller ögon. Sjukdomen går i skov, dvs. besvären blossar upp i 
perioder, vilka är svåra att förutse. Hur svår sjukdomen kommer att bli för den enskilde 
individen är mycket varierande och det saknas idag pålitliga markörer för att förutspå 
förloppet. Orsaken till Crohns sjukdom är inte helt känd, men flera faktorer samverkar, 
så som genetiska avvikelser, miljöfaktorer och förändringar i immunförsvarets 
funktion.  
 
Denna avhandling omfattar fyra olika studier av Crohns sjukdom hos barn. Dessa 
studier syftar till att öka kunskapen kring sjukdomen och vad som påverkar dess 
förlopp och att därigenom bättre kunna förutse behoven hos den enskilde patienten.  
 
Deltagarna i studierna är barn och ungdomar med diagnosticerad Crohns sjukdom som 
kontrolleras på barngastroenterologiska enheter i huvudsakligen Stockholm, Paris och 
London. I studie 3 ingår även en delstudie på råttor.  
 
I studie 1 undersöks förekomst och betydelse av varianter av den s.k. NOD2/CARD15-
genen som finns hos upp till 60 % av personer med Crohns sjukdom i södra Europa och 
i Nordamerika. Det visar sig att i gruppen med svenska barn med Crohns sjukdom (58 
st) är det endast 8,6 % som är bärare av någon variant i denna gen. På grund av den 
låga förekomsten av dessa genvarianter hittas inga associationer till en särskild 
sjukdomsbild, men ett samband mellan NOD2/CARD15-varianter och sjukdom 
lokaliserad i tunntarmen har rapporterats av andra forskare. Fynden i studie 1 är 
intressanta eftersom det tycks som om gruppen med svenska barn med Crohns sjukdom 
inte bara har lägre förekomst av just dessa genvarianter, utan också har mer tjocktarms- 
än tunntarmslokalisation av sin sjukdom. Lägre förekomst av NOD2/CARD15-
varianter har på senare tid även rapporterats från grupper av vuxna Crohn-patienter i 
Sverige och i andra nordiska länder. 
 
I studie 2 undersöks 191 barn med Crohns sjukdom med avseende på om det finns 
något samband mellan ålder och lokalisation av inflammationen vid insjuknandet. Det 
visar sig att inflammation i nedersta delen av tunntarmen (ileum) är ovanligt hos barn 
som är diagnosticerade före 9 års ålder, och att sannolikheten för sådan lokalisation 
sedan ökar med stigande ålder upp till vuxen ålder. Således är det vanligast att de 
yngsta barnen med Crohns sjukdom har inflammation i tjocktarmen. Att de allra yngsta 
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har mer tjocktarmslokalisation har bekräftats i flera andra studier. En förklaring till 
detta samband skulle kunna vara att den s.k. lymfoida vävnaden, som föreslagits som 
inflammationens startplats, förekommer oberoende av ålder i tjocktarmen, medans den 
i tunntarmen utvecklas med stigande ålder upp till vuxen, och sedan tillbakabildas. 
 
I studie 3 undersöks om reducerad längdtillväxt hos barn med Crohns sjukdom 
korrelerar till någon särskild variant av den gen som styr produktionen av ett 
inflammationsbefrämjande ämne som heter interleukin (IL)-6. Vid tidpunkt för Crohn-
diagnos hos de 153 undersökta barnen, visar det sig att barnen med en specifik variant 
av genen är mer tillväxthämmade jämfört med de barn som har andra genvarianter. 
Detta, och resultatet från en parallell studie på råttor, talar för att IL-6 och en specifik 
variant av IL6-genen bidrar till hämmad längdtillväxt vid aktiv Crohns sjukdom. 
Sannolikt finns det på liknande sätt olika varianter även av andra gener som påverkar 
t.ex. risken för tillväxthämning eller mer komplicerad sjukdom. 
 
I studie 4 undersöks betydelsen av att s.k. granulom hittas i de biopsier (små bitar av 
tarmslemhinnan) som tas i samband med utredning av Crohns sjukdom hos barn. 
Granulom består av en ansamling av särskilda celler från immunförsvaret som ger en 
specifik bild vid mikroskopisk granskning av biopsierna. Hos ungefär hälften av de 45 
studerade barnen hittas granulom och förekomsten visar sig kunna vara relaterad till ett 
svårare sjukdomsförlopp. Tecken på aggressivare sjukdom är i denna studie förekomst 
av inflammation i övre mag-tarm-kanalen (matstrupe, magsäck eller tolvfingertarm) 
och att behandling med mer potenta läkemedel (s.k. immunmodulerare) påbörjas 
kortare tid efter sjukdomsstart.  
 
Studie 4 är samtidigt en långtidsuppföljning, mellan 9 och 18 år efter insjuknandet, av 
dem som fått Crohn-diagnosen som barn eller tonåring och som nu blivit vuxna. I den 
svenska gruppen med barn med Crohns sjukdom är det ovanligt med tillväxthämning 
vid såväl sjukdomsstart som vid vuxen ålder då slutlängd uppnåtts. Det tycks också 
som om Crohn-relaterade komplikationer (t.ex. fistlar eller stenoser) och kirurgi är 
något mindre vanligt i denna grupp, jämfört med vad som rapporterats från andra delar 
av Europa och Nordamerika. Man kan spekulera i om en av förklaringarna till detta 
skulle kunna vara skillnader i sjukdomslokalisationen eftersom andra studier har visat 
att både kirurgi och tillväxthämning är vanligare vid sjukdomsutbredning i tunntarm 
och tunntarmsutbredning tycks mindre vanligt i gruppen som studerats i studie 1 och 4. 
 
Utvecklingen av Crohns sjukdom påverkas av en komplicerad kombination av 
genetiska, miljömässiga och immunologiska faktorer och dessa faktorer har även 
betydelse för sjukdomsförlopp, hur individens sjukdom svarar på olika behandlingar, 
komplikationer, sjukdomsprognos etc. Studierna i den här avhandlingen har bidragit till 
den hela tiden växande kunskapen om hur olika faktorer har betydelse för 
sjukdomsuttryck och förlopp av Crohns sjukdom hos barn. Exakt hur dessa faktorer 
samverkar får framtida forskning avslöja. Storskaliga multicenterstudier, där befintlig 
information om genetik, klinik, serologi och miljö kombineras, kommer sannolikt att 
krävas för att kunna fastställa framtida risker och behov av behandling hos den enskilda 
patienten. Förhoppningen är att då kunna utveckla individuella terapistrategier som 
syftar till förbättrad prognos och livskvalitet för patienten. 
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